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Abstract
Background: Deficiency of Von Willebrand Factor Cleaving Protease (VWFCP) has been
implicated as the cause of Thrombotic Thrombocytopenic Purpura (TTP). TTP is a life-
threatening disease characterised by microangiopathic thrombosis due to accumulation of
Ultralarge Von Willebrand Factor (ULVWF) multimers. The clinical features of TTP include
microangiopathic haemolysis and thrombocytopenia. TTP is being seen with increased
frequency in the context of HIV. However, in the context of HIV infection, cytopenias are often
multifactorial in nature and levels of VWFCP in HIV-related thrombocytopenia have not
specifically been assessed.
This study assessed VWFCP activity in the setting of patients with HIV and thrombocytopenia
in the absence of TTP, in order to determine the utility of a VWFCP assay in the diagnosis of
HIV-related TTP. Acquired VWFCP deficiency is generally assumed to be due to the
presence of autoantibody inhibitors to the enzyme, but limited data are available regarding
VWFCP activity in HIV positive TTP patients. There is also currently no assay available for
measuring VWFCP activity in our laboratory.
Aim of Study: To establish a practical assay for VWFCP activity for routine use in our
laboratory. The rapid collagen binding assay, based on the ELISA method of Rick, et al.,
2002, was chosen. This was initially used to measure VWFCP activity in patients with HIV
with and without thrombocytopenia (of any cause except TTP), in order to ascertain whether
assessment of VWFCP activity is likely to be of value in facilitating early diagnosis of HIV
related TTP.
The ELISA assay was performed to establish cut-off values for VWFCP in HIV negative
controls and two HIV positive groups (HIV thrombocytopenia / low platelets and HIV normal
platelets). Depending on the outcome of this, the assay could then be performed to assess
VWFCP activity in HIV positive patients with TTP.
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Methods: The rapid collagen binding assay for VWFCP activity was established and
optimised for routine use in our laboratory. The cut-off values for percentage Residual
Collagen Binding Activity (RCBA) in both HIV negative and HIV positive groups were
identified. The assay could then be used to assess VWFCP activity in 20 HIV positive patients
with TTP at the time of presentation. In patients with reduced VWFCP activity, patient plasma
was mixed with normal pool plasma in a 50:50 mix, to assess for the presence of inhibitors.
Correlation of VWFCP activity, inhibitors and other laboratory and clinical parameters were
performed.
Results: The cut-off values for percentage RCBA in both HIV negative (<37.12%) and HIV
positive (<51.51%) patients were established. The % RCBA for the HIV negative control
group was statistically significantly different from the HIV positive group with normal platelets
(p=0.0001) and from the HIV positive group with low platelets (p=0.0006). The cut-off value in
the two HIV positive patient groups was higher than for HIV negative control patients,
indicating mildly reduced VWFCP enzyme activity in HIV positive patients (regardless of the
platelet count), in the absence of TTP. However, no significant difference in the cut-off value
was noted between HIV positive patients with low platelet counts versus HIV positive patients
with normal platelet counts (p=0.7783). The assay could therefore be used in HIV positive
patients with TTP.
VWFCP activity was assessed in twenty HIV positive patients with TTP. Two groups of HIV
positive patients with TTP were identified based on VWFCP activity. Six patients (30%) had
normal (one borderline) VWFCP activity (RCBA <51.51%), while the remaining 14 patients
had severely reduced VWFCP levels (RCBA >90%). Of the patients with reduced VWFCP
activity, only 5 patients had a detectable inhibitor, while an inhibitor was not detected in the
remaining 8 patients.
Conclusion: The rapid collagen binding ELISA assay is a cost effective semi-quantitative
assay for the assessment of VWFCP activity. VWFCP activity in HIV positive patients appears
to be slightly lower, however is not related to the platelet count. This suggests a slight
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baseline deficiency of VWFCP in the setting of HIV. The baseline VWFCP cut-off value in HIV
allowed assessment of HIV positive patients with TTP. The results suggest heterogeneity of
VWFCP activity in HIV-related TTP. A negative result (normal VWFCP activity) does not
exclude TTP in patients with HIV-related TTP and other pathogenic factors may therefore be
involved.
Key Words: Von Willebrand Factor Cleaving Protease (VWFCP); Thrombotic
Thrombocytopenic Purpura (TTP); Human Immunodeficiency Virus (HIV); Von Willebrand
Factor (VWF); Residual Collagen Binding Activity (RCBA).
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11. Introduction
1.1 Background
In the context of HIV infection there are numerous causes for anaemia and thrombocytopenia
(Blazes & Decker, 2004; Cines, Konkle & Furlan, 2000; Karpatkin, Nardi & Green, 2002).
Thrombotic Thrombocytopenic Purpura (TTP) is one of the causes which constitutes a
haematological emergency. TTP is being seen with increasing frequency in association with
HIV infection (Cines, et al 2000; Karpatkin, Nardi & Green, 2002). Early diagnosis and
aggressive therapy with plasmapheresis is essential for survival in this condition which used
to carry a mortality of greater than 90% (Cines. et al., 2000; Rock, 2000). However, the
diagnosis of TTP can be particularly difficult in the context of HIV, where numerous other
causes for the cytopenias may be present.
TTP is a disease characterized by microvascular platelet aggregation and thrombus formation
in selected tissue beds resulting in a pentad of: thrombocytopenia, microangiopathic
haemolytic anaemia, renal failure, neurological symptoms and fever (Amorosi & Ultman,
1966; Cines, Konkle & Furlan, 2000; Moake, 2002; Rock, 2000). The differential diagnosis for
TTP includes other thrombotic microangiopathies such as: Disseminated Intravascular
Coagulation (DIC), Haemolysis Elevated Liver enzymes and Low Platelets (HELLP
syndrome), Haemolytic Uraemic Syndrome (HUS) and Pre-Eclamptic Toxaemia (PET).
Distinction between these possibilities depends on clinical correlation and background
laboratory investigations including: a full blood count, a DIC screen, LDH (lactate
dehydrogenase) level, haptoglobin level, liver function tests, renal function tests (Urea and
Electrolytes) and examination of the peripheral blood smear to detect red cell fragmentation
suggestive of microangiopathic haemolysis.
One cannot wait for the full pentad of symptoms of TTP to develop, as early diagnosis and
treatment are imperative to decrease the high mortality of this disease. However, as the
therapy for TTP is very costly (approximately R10 000 per episode of therapeutic
plasmapheresis), improved diagnostic tools would be of great value to confirm the diagnosis
2of TTP and avoid the use of costly therapy in conditions which cause similar features to TTP,
but require different management.
A possible key role for Von Willebrand Factor (VWF) in the pathogenesis of TTP was first
suggested by Moake and co-workers in 1982, who postulated a deficiency of a VWFCP as
the cause for the presence of Ultralarge VWF (ULVWF) multimers found in the plasma of four
patients with chronic relapsing TTP (Moake, et al., 1982). The interest in TTP is likely
associated to its striking presentation in previously healthy individuals, its rapid progression
and often fatal clinical course and to the fact that early diagnosis can be life saving (Levy,
Motto & Ginsburg, 2005).
In 2001, several groups identified ADAMTS13 (a disintegrin-like and metalloprotease with
thrombospondin type 1 motif 13) , a novel member of the ADAMTS family of
metalloproteases, as the Von Willebrand Factor Cleaving Protease (VWFCP) (Furlan, Robles
& Lämmle, 1996; Tsai, 1996) and deficiency of ADAMTS13 was implicated in the
pathogenesis of TTP (Furlan, et al., 1998). Measuring VWFCP activity in the setting of TTP as
well as other pathological conditions is a focus of substantial research (Levy, Motto &
Ginsburg, 2005). A deficiency of VWFCP (either hereditary or acquired due to the presence of
an autoantibody inhibitor) is present in many cases of TTP (Cines, Konkle & Furlan, 2000;
Levy, et al., 2001; Ruggenenti, Noris & Remuzzi, 2001). The decreased activity of VWFCP,
results in accumulation of ULVWF, which contribute to the pathogenesis of TTP by binding to
platelets, causing platelet aggregates and intravascular thrombosis. This leads to tissue
ischaemia and haemolysis (Levy, et al., 2001; Ruggenenti, Noris & Remuzzi, 2001).
Congenital ADAMTS13 deficiency has been shown to be on the basis of mutations in the
encoding gene (Levy, et al., 2001) whilst acquired deficiency may be caused by
autoantibodies (Furlan, Robles & Lämmle, 1996; Tsai, 1996). These autoantibodies may be
idiopathic or arise secondary to various conditions including autoimmune disease, pregnancy,
drugs and infections (Moake, 2002). The sensitivity of VWFCP deficiency for the diagnosis of
TTP is somewhat controversial ranging from 33-100% in studies with similar data for
3specificity (Furlan, et al., 1998; Tsai, 2003; Raife, et al., 2002). Furthermore acquired
deficiency may occur in the absence of detectable antibodies (Peyvandi, et al., 2004; Zheng,
et al., 2004) suggesting other factors may be important in the pathogenesis.
The occurrence of TTP in association with HIV infection is now well recognized (Hymes &
Karpatkin, 1997; Blazes & Decker, 2004). The pathophysiology of TTP in this setting is not
definitively known and there is limited data available regarding VWFCP activity or the
presence of autoantibodies in these patients. The majority of large series assessing these
parameters either do not include (Peyvandi, et al., 2004; Vesely, et al., 2003; Zheng, et al.,
2004) or specifically exclude (Coppo, et al., 2005) HIV positive patients. In addition, it has
been shown that levels of VWFCP may be altered in other settings in the absence of TTP
(Reiter, et al., 2003; Mannucci, et al., 2001), and levels of VWFCP in patients with HIV related
thrombocytopenia have not specifically been assessed.
The activity of VWFCP has been shown to be normal in many patients with a similar
condition, HUS, thus indicating that evaluation of VWFCP levels may be helpful in the
differential diagnosis (Levy, et al., 2001; Ruggenenti, Noris & Remuzzi, 2001). Conventional
assays for VWFCP activity are expensive, cumbersome and not practical for routine use
(Cines, Konkle & Furlan, 2000; Rick, et al., 2002; Aronson, Krizek & Rick, 2001; Furlan, et al.,
1998; Tsai & Lian, 1998). For example, one other assay for measuring VWFCP activity,
requires preparation of substrate Von Willebrand Factor which is impractical in a routine
laboratory setting (Krizek & Rick 2000; Gerritsen, et al., 1999). Initial methods for assessment
of the VWFCP took 24 to 48 hours and involved electrophoresis and specialized reagents
(Furlan, et al., 1998; Tsai & Lian, 1998). There is currently no assay available for measuring
VWFCP activity in our laboratory.
Recently, a less complicated “shorter” assay has been described, which appears to be more
applicable for routine use (Aronson, Krizek & Rick, 2001; Rick, et al., 2002). This method is
based on a rapid collagen binding assay for VWFCP (Aronson, Krizek & Rick, 2001; Rick, et
al., 2002). This assay has been validated against a previous VWFCP assay (Aronson, Krizek
4& Rick, 2001; Rick, et al., 2002) and by analysis of VWF multimer patterns. This assay yields
the same diagnostic information as others, at less cost and time, without the need for a
prepared substrate (Aronson, Krizek & Rick, 2001; Rick, et al., 2002).
1.2 Summary of Research Hypothesis
 To establish a practical assay for VWFCP activity for routine use in our laboratory,
based on the method of Rick and co-workers (Rick, et al., 2002).
 To measure VWFCP activity in patients with HIV infection with low platelet counts
(other than TTP) and normal platelet counts to determine cut-off levels for normal
VWFCP activity in HIV and to assess for any significant differences from HIV negative
individuals or between groups.
If the outcome of initial studies revealed:
 the cut-off value in the HIV positive patients to be similar to the HIV negative patients
and not significantly different in HIV positive patients with low platelet counts (due to
causes other than TTP) then this assay would be expected to be useful as a
diagnostic tool in the setting of HIV positive patients with TTP. VWFCP activity could
then be assessed in patients HIV-related TTP as an additional component of this
MMED project.
1.3 Clinical manifestations of TTP
TTP is associated with microvascular platelet thrombi which causes microngiopathic
haemolytic anaemia (with red cell fragmentation on the peripheral smear) and
thrombocytopenia (Allford, et al., 2003; Wyrick-Glatzel, 2004). A shift toward earlier diagnosis
has occurred and the full pentad of clinical manifestations of TTP, comprising
microangiopathic haemolytic anaemia, thrombocytopenia, with associated fever, neurological
symptoms and renal dysfunction may not be present (Sadler, 2006). Early recognition and
treatment of TTP is critical to outcome (Wyrick-Glatzel, 2004). At presentation up to 35% of
5patients with TTP may not have neurological signs or symptoms (Rock, et al., 1991). Fever
and renal impairment are seen in a minority of cases (Rock, et al., 1991; Rock, et al., 1998).
A diagnosis of TTP may be made in the presence of microangiopathic haemolytic anaemia
and thrombocytopenia in the absence of any other identifiable cause (Allford, et al., 2003).
Neurological symptoms include headache, transient sensorimotor deficits, seizure, altered
mental status, visual impairment and coma (Allford, et al., 2003; Wyrick-Glatzel, 2004). Micro-
occlusive or micro-haemorrhagic vascular changes are suggested as causes for the latter
symptoms (Wyrick-Glatzel, 2004). Presence of coma at presentation is considered a poor
prognostic indicator (Pereira, et al., 1995; Sarode, et al., 1997). Other complications that may
occur include gastrointestinal ischaemia and serous retinal detachment (Allford, et al., 2003).
Red cell haemolysis results from passage of red cells in microvasculature occluded by
platelet thrombi, and is not immune in nature (Wyrick-Glatzel, 2004). Degree of haemolysis
may be confirmed with elevation of LDH level, unconjugated hyperbilirubinaemia and raised
reticulocyte production index. The coagulation studies are usually normal in TTP as compared
to DIC (Wyrick-Glatzel, 2004). Raised D-Dimers may be found in association with TTP, in
particular HIV-associated TTP (Gunther & Dhlamini, 2007).
1.4 Pathogenesis of TTP
1.4.1 Historical perspective and the role of VWFCP/ ADAMTS13
In 1924, Dr Eli Moschcowitz described a 16 year old girl who had developed acute onset of
haemolytic anaemia, fever, petechiae which was soon followed by paralysis, coma and death
(Moschcowitz, 1924). Most of the organs of this patient demonstrated occlusion of terminal
arterioles and capillaries by hyaline thrombi without inflammation (Lian, 2005). Subsequently
intraluminal thrombi were shown to comprise predominantly platelets (Gore, 1950; Feldman,
et al., 1966; Asada, et al., 1985). Red cells fragment as blood flows through microvessels
which are occluded by platelet thrombi, and microangiopathic haemolysis with raised LDH
levels then occurs (Lian, 2005).
6TTP usually occurs in adults (Lian, 2005), a paediatric form of the disease from early
childhood with repeated episodes of anaemia and thrombocytopenia was reported by
Schulman in 1960 and by Upshaw in 1978 and is termed Upshaw-Schulman syndrome
(Schulman, et al., 1960; Upshaw, 1978; Lian, 2005). Patients with this syndrome were noted
to respond to plasma infusion and Upshaw thought the disease was due to a deficiency of a
plasma factor that may promote red cell and platelet survival (Upshaw, 1978).
Four patients with chronic relapsing TTP (two were brothers) with plasma deficiency of
VWFCP, were described in 1997 (Furlan, et al., 1997). Subsequently it was reported that
deficiency in VWFCP was due to autoantibodies in acquired idiopathic acute TTP (Furlan, et
al., 1998; Tsai & Lian, 1998). A multicentre retrospective study on the prevalence of VWFCP
deficiency in patients with familial and acquired TTP, confirmed an association of TTP with a
hereditary as well as an acquired VWFCP deficiency (Furlan, et al., 1998). A marked
decrease in VWFCP activity (<5% of normal plasma) was noted in 26 of 30 patients during an
acute event (6 familial and 24 non-familial cases) and an inhibitor of VWFCP was detected in
20 of 24 patients with non-familial TTP but in none of the patients with familial TTP (Furlan, et
al., 1998).
Tsai and co-workers independently confirmed a deficiency of VWFCP in TTP patients and
found no activity in the plasma samples of 37 patients during the acute episode (Tsai & Lian,
1998). Immunoglobulin G antibodies with inhibitory activity against VWFCP were detected in
two-thirds of samples collected during the acute event (Tsai & Lian, 1998). Inhibitors were not
detected in 16 samples obtained during the remission of TTP or in plasma samples of 74
normal subjects or patients with haemolysis, thrombocytopenia or thrombosis from other
causes (Tsai & Lian, 1998).
In 2001, A Disintegrin-like And Metalloprotease with ThromboSpondin type 1 motif 13
(ADAMTS13) gene was identified to code for a VWF protease protein, through the use of
genetic linkage studies of affected family members (Levy, et al., 2001) or peptide sequence
analysis of purified VWFCP (Fujikawa, et al., 2001; Gerritsen, et al., 2001; Zheng, et al.,
72001). These findings firmly establish the importance of the role of VWF and VWFCP in the
pathogenesis of TTP (Lian, 2005).
As the identity of the ADAMTS13 gene was confirmed as the VWFCP (Fujikawa, et al., 2001;
Gerritsen, et al., 2001), the terms VWFCP and ADAMTS13 are used interchangeably in the
write-up of my MMED research report. ULVWF multimers were considered to be pathogenic
in patients with chronic relapsing TTP (Moake, et al., 1982). ULVWF multimers were reported
in the plasma of four patients with chronic relapsing TTP (Moake, et al., 1982) and some
cases of acute TTP (Moake, et al., 1986). The investigators suggested that the accumulation
of ULVWF multimers might be due to the excessive release of VWF from the endothelial cells
and/or impaired degradation of the highly multimeric forms of VWF by an enzyme and as a
result TTP developed (Moake, et al., 1982; Moake, et al., 1986). In the microvessels of TTP
patients, an abundance of VWF with little fibrin, in platelet thrombi was described, further
supporting a role for VWF in TTP (Asada, et al., 1985).
The ADAMTS13 mediated cleaving process results in the production of smaller VWF
multimers that circulate after cleavage and do not induce platelet adhesion or aggregation
during normal blood flow (Wyrick-Glatzel, 2004). The binding affinity of the large VWF
multimers is ten times higher than that of the smaller molecular forms of VWF (Federici, et al.,
1989). The ULVWF multimers are extremely adhesive due to the increased number of binding
sites for platelets compared with the smaller forms (Wyrick-Glatzel, 2004).
ULVWF multimers released from endothelial cells are even more effective in inducing platelet
agglutination under conditions of high shear stress than the largest forms of VWF circulating
in normal plasma (Moake, et al., 1986). In the presence of normal physiology, plasma is
devoid of ULVWF multimers due to cleavage by ADAMTS13 as they emerge from the
endothelial cell surface (Wyrick-Glatzel, 2004). In the absence of ADAMTS13, ULVWF
multimers accumulate unchecked in the circulation resulting in VWF-platelet binding and
microvascular platelet thrombosis (Tsai, 2003).
8Conditions that cause increased VWF secretion and decreased ADAMTS13 activity may
favour the clinical entity of TTP. Deficiency of ADAMTS13 is a very strong risk factor for TTP,
however the development of acute TTP requires a trigger that possibly causes activation or
apoptosis of the microvascular endothelial cells (Furlan & Lämmle, 2001). ULVWF multimers
are secreted and ADAMTS13 deficiency in this setting may trigger the sequence of events
resulting in thrombotic microangiopathy (Furlan & Lämmle, 2001). Studies have documented
that <5% normal ADAMTS13 activity is found in most patients with acute acquired TTP
(Bianchi, et al., 2002). In ADAMTS13 deficiency, there is no cleavage of the ULVWF
multimers as they emerge from the endothelial cells and the ULVWF multimers remain
anchored to the endothelial cells forming ‘beads on a string’ structures (Wyrick-Glatzel, 2004).
P-Selectin molecules with transmembrane domains appear to partially mediate this anchor
activity of ULVWF multimers to the endothelial cells. P-Selectin is synthesised by cells that
also produce VWF and is stored in the same endothelial cell and platelet alpha granules as
VWF. P-Selectin is considered to play an essential role in anchoring VWF to endothelial cells
as well as in inducing platelet string detachment from the endothelial cell surface (Wyrick-
Glatzel, 2004).
Circulating platelets initially adhere via the interaction of VWF with the glycoprotein Ib
membrane receptor and additional platelets aggregation during blood flow via activated IIb/IIIa
complexes, forming potentially occlusive microvascular platelet thrombi (Wyrick-Glatzel,
2004).
Platelet adhesion and aggregation occurs in vitro in the presence of conditions of high shear
stress (Arya, et al., 2002). Many of the platelet strings may be as long as three millimetres
and in the absence of ADAMTS13 activity, these platelet strings may detach from the
endothelial cell and ‘embolise’ to blood vessels thereby causing organ ischaemia (Wyrick-
Glatzel, 2004).
9Refer to Figure 1 for an illustration of the pathogenesis of idiopathic TTP caused by
ADAMTS13 deficiency.
Figure 1. Schematic depiction of the pathogenesis of idiopathic TTP caused by ADAMTS13
deficiency. ULVWF multimers adhere to exposed connective tissue in vessel wall or to
endothelial cells. Thereafter platelets adhere to VWF through platelet glycoprotein Ib (GPIb).
In the presence of flowing blood, the VWF within the platelet rich thrombus is stretched and
cleaved by ADAMTS13 and thrombus growth is limited. If there is a deficiency or absence of
ADAMTS13, VWF-dependent platelet aggregation continues and eventually microvascular
thrombosis with the development of TTP occurs. Diagram from: Sadler, 2006. TTP a moving
target. American Society of Haematology Education Program Book, pp. 416.
1.4.2 Antibodies against ADAMTS13
In the literature, reported autoantibodies against ADAMTS13 in patients with acquired
idiopathic TTP, ranged from 30% to 83% (Furlan, et al., 1998; Tsai & Lian, 1998; Veyradier, et
al., 2001; Vesely, et al., 2003; Peyvandi, et al., 2004a; Matsumoto, et al., 2004). The
autoantibodies may be IgM or IgG in nature (Furlan, et al., 1998; Rieger, et al., 2005).
The autoantibodies may be transient in nature and may disappear after plasmapheresis has
been performed for several days, whereas in some cases autoantibodies may persist for long
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periods (Lian, 2005). In three patients with TTP, the major epitopes of antibodies were found
to reside within the cysteine-rich/spacer domains (Soejima, et al., 2003).
ADAMTS13 epitope mapping of autoantibodies from 25 patients with acute TTP (severe or
borderline to severe ADAMTS13 deficiency and protease inhibiting antibodies ), by Klaus and
co-workers, showed that all 25 patients had antibodies reacting with ADAMTS13 Cys-
rich/spacer domain, 16 of the 25 plasmas reacted with the two CUB domains, 14 of the 25
plasmas with the catalytic/disintegrin/thrombospondin type 1 domains, 14 of the 25 plasmas
with the first thrombospondin type 1 domain, 7 of 25 with the thrombospondin type 2 to 8
domains and 5 of the 25 plasmas recognised the propeptide (Klaus, et al., 2004).
This demonstrates that in acute TTP, antibodies to different antigenic regions of ADAMTS13
are present (Lämmle, Kremer Hovinga & Alberio, 2005). Antibodies directed against the Cys-
rich/spacer domain are likely to account for inhibition of ADAMTS13 activity in static in vitro
assays. Antibodies to other antigenic sites may impair ADAMTS13 interaction with endothelial
cell anchored ULVWF in vivo, with such antibodies leading to the clinical entity of TTP
(Lämmle, Kremer Hovinga & Alberio, 2005).
Other pathological mechanisms that do not involve the ADAMTS13-VWF interaction may also
lead to a syndrome that is clinically indistinguishable from that of acquired ADAMTS13
deficiency (Lämmle, Kremer Hovinga & Alberio, 2005).
Non-neutralising IgG and IgM antibodies have been reported in one patient (Scheiflinger, et
al., 2003) and are considered to influence the half-life of ADAMTS13 and cause in vivo
ADAMTS13 deficiency in some TTP patients (Lian, 2005). Autoantibodies may occur due to
the interaction of a susceptible host to endogenously produced triggers such as denatured
proteins and cytokines from inflammation and tissue injury or to environmental factors
including non-infectious and infectious agents (Lian, 2005). ADAMTS13 autoantibodies have
been reported in association with clopidogrel and ticlopidine (Tsai, et al., 2000; Bennett, et al.,
2000).
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1.4.3 Inhibitory effect of Haemoglobin on ADAMTS13
Studt and co-workers showed that in a pre-mortem serum sample of a paediatric patient with
TTP, a severe ADAMTS13 deficiency was documented and sequencing of the ADAMTS13
gene revealed a homozygous mutation confirming hereditary ADAMTS13 deficiency.
However the patient’s serum had a profound ADAMTS13 inhibitor effect that was not
attributable to purified antibody but caused by haemolysis products present in the sample.
Subsequent investigation revealed that haemoglobin had an inhibitory effect on ADAMTS13
(Studt, et al., 2005). Inhibition of ADAMTS13 activity occurred at haemoglobin concentrations
that would normally be associated with strong intravascular haemolysis as found in
incompatible red cell transfusion or immune-mediated haemolytic anaemia (Studt, et al.,
2005). These conditions are not usually associated with TTP and it is not certain whether
short-lived increase of free haemoglobin in plasma will lead to clinically relevant ADAMTS13
inhibition (Studt, et al., 2005). In this case, the serum haemoglobin concentration of 17g/l was
probably due to in vitro haemolysis in stored native whole blood (Studt, et al., 2005).
Nonetheless, marked haemolysis and the presence of haemoglobin affect most current
ADAMTS13 assays, lowering of values for ADAMTS13 activity should be expected under
these circumstances and inhibitor screening may lead to the incorrect assumption of
ADAMTS13 inhibitory antibodies (Studt, et al., 2005). However whether the capacity of
haemoglobin to inhibit ADAMTS13 is of any physiological or pathophysiological relevance is
still to be ascertained (Studt, et al., 2005).
1.4.4 Pathogenic mechanisms beyond deficiency of ADAMTS13 and autoantibodies
A severe deficiency of ADAMTS13 is certainly a predisposing risk factor for the development
of TTP (Lian, 2005). Even in patients with hereditary TTP with a life-long severe ADAMTS13
deficiency, clinical symptoms of TTP may only develop in the second or third decade and the
episodes of clinical symptoms are often associated with certain triggers such as pregnancy or
surgery (Lian, 2005). In between clinical relapses of TTP in patients with chronic relapsing
TTP, ULVWF multimers persist despite no other signs of disease activity, thereby suggesting
that ULVWF multimers cannot be the only risk factor for microvascular thrombosis
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(Galbusera, et al., 1999b). Initially Furlan and co-workers and Tsai and co-workers, reported
that 83% (20 of 24) and 100% (37 of 37) of patients with acute Idiopathic TTP had severe
ADAMTS13 deficiency of less than 5% (Furlan, et al., 1998; Tsai & Lian, 1998). However later
studies in patients with idiopathic TTP demonstrated severe ADAMTS13 deficiency in 33%
(16 of 48), 48% (48 of 100), 53% (56 of 108), 60% (56 of 93), 80% (16 of 20) and 91% (21 of
23) as reported by Vesely and co-workers, Peyvandi and co-workers , Matsumoto and co-
workers, Kremer Hovinga and co-workers, Zheng and co-workers and Böhm and co-workers,
respectively (Vesely, et al., 2003; Peyvandi, et al., 2004a; Matsumoto, et al., 2004; Kremer
Hovinga, et al., 2004; Zheng, et al., 2004; Böhm, et al., 2005). The above observations
suggest that in approximately 40% of patients with acquired idiopathic TTP, ADAMTS13
deficiency may not be the cause of microvascular platelet thrombi (Lian, 2005).
Autoantibody response could be triggered by infection, inflammation, tissue injury or drugs
(Lian, 2005). The formation of microvascular platelet thrombi in patients with acquired TTP
without ADAMTS13 deficiency may be caused by endothelial injury and/or platelet
aggregation triggered by various stimuli that may be related to inflammation, infectious
agents, immune response or chemicals (Lian, 2005). Some triggering agents may cause
vascular injury/platelet aggregation and result in TTP without ADAMTS13 autoantibody
formation (Lian, 2005). Lämmle and co-workers suggest that not all patients diagnosed with
idiopathic TTP may have severe ADAMTS13 deficiency as measured with static protease
activity assays (Lämmle, Kremer Hovinga & Alberio, 2005) as opposed to suggesting other
different aetiological causes for idiopathic TTP aside from severe ADAMTS13 deficiency, as
suggested by Lian (Lian, 2005).
 Intravascular platelet aggregation secondary to substances other than VWF
A platelet agglutinating protein was isolated from the plasma of a patient with typical
manifestations of TTP, with a molecular weight of 37,000 (p37) (Siddiqui & Lian, 1986).
Independent of VWF, p37 induces agglutination of homologous and autologous platelets and
binds specifically to platelet CD36. Hirudin, heparin (in the presence of antithrombin) or
aspirin do not inhibit platelet aggregation caused by p37 (Lian, 2005). Platelet aggregation
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induced by p37 is inhibited by IgG from normal adults and from the same patient after
recovery (Lian, 2005).
In two, of another four TTP plasmas possessing platelet-aggregating activity, p37 was present
and it was not documented in normal controls, patients with disseminated intravascular
coagulopathy or idiopathic thrombocytopenic purpura (Lian, 2005). The presence of p37 is
therefore suggested in a subset of patients with TTP (Lian, 2005). Platelet aggregating factors
of different molecular mass such as 900 (Lian, 1980) and 58 (Chen, et al., 1989) have been
documented and the platelet aggregating factors in TTP plasma are therefore considered
heterogeneous (Lian, 2005).
 Antibodies against platelets and endothelial cells
Several studies have investigated the mechanism of endothelial damage in TTP. In the
plasma of patients with TTP and HUS, lytic anti-endothelial antibodies have been identified
(Burns & Zucker-Franklin, 1982; Leung, et al., 1988; Wight, et al., 1999). In vitro, endothelial
cell-reactive plasmas were found to induce human platelet aggregation (Burns & Zucker-
Franklin, 1982), thereby suggesting that TTP plasma may cause both endothelial cells
damage and direct thrombotic vascular occlusion resulting in TTP (Furlan & Lämmle, 2001).
Studies have assessed the presence of anti-CD36 antibodies in the setting of TTP (Tandon,
Rock & Jamieson, 1994; Schultz, et al., 1998; Wight, et al., 1999). CD36, also known as
platelet glycoprotein IV, is an integral membrane protein expressed by platelets and some
other cells including endothelial cells (Furlan & Lämmle, 2001). Of interest is that endothelial
cell CD36 expression is limited to capillary endothelial cells (Swerlick, et al., 1992). CD36 is
the receptor of a previously recognised platelet-aggregating factor (the platelet-agglutinating
37kDa protein) present in the plasma of TTP patients (Lian, et al., 1991; Siddiqui & Lian,
1986). It is not known whether anti-endothelial and anti-platelet antibodies induce endothelial
cell damage and apoptosis with subsequent release of ULVWF multimers or whether they are
directly involved in the formation of platelet microvascular aggregates (Furlan & Lämmle,
2001).
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In addition, antibodies against endothelial cells and platelets may arise secondary to immune
responses to inflammatory events in TTP patients, which may lead to the exposure of crypto-
antigens or the expression of cellular neo-antigens (Rock, 2000). Endothelial cell antibodies
have also been documented in patients with disorders which are unrelated to TTP (Rock, et
al., 1994). Another study suggested that in the setting of TTP, endothelial cell or platelet
reactive antibodies were not prevalent and more than a third of reactive antibodies were
human leucocyte antigen alloantibodies (Raife, et al., 1999). Of note is that complement is not
depleted in the setting of acute TTP (Ucar, et al., 1994). Depleted complement levels would
be expected if directly toxic endothelial cell antibodies were involved in TTP pathogenesis
(Furlan & Lämmle, 2001). Therefore the contribution of endothelial cell injury mediated by
antibodies as a primary aetiological factor in the setting of TTP is controversial (Furlan &
Lämmle, 2001).
 Inflammatory cytokines and apoptosis
By electron microscopy, ultrastructural alterations in microvascular endothelial cells have
been noted in TTP patients, showing swollen mitochondria and cytoplasmic vacuoles,
reflecting early apoptotic lesions (Furlan & Lämmle, 2001). Even in the absence of platelet
microthrombi, these lesions have been documented, suggesting that these changes are not
merely a consequence of vascular occlusion (Furlan & Lämmle, 2001).
Apoptosis has been induced in human endothelial cells of dermal microvascular origin by the
plasma of patients with idiopathic TTP or HIV associated microangiopathy (Laurence, et al.,
1996). Detachment of endothelial cells from the renal microvasculature and detection of these
cells in the circulation supports the presence of an apoptotic process (Lefevre, et al., 1993).
Plasma from patients with TTP and sporadic HUS induced apoptosis and expression of the
apoptosis associated protein Fas (CD95) in microvascular endothelial cells of cerebral, renal
and dermal origin but not in those of hepatic or pulmonary origin and this difference parallels
the in vivo pathology of TTP/HUS whereby the pulmonary and hepatic vasculature are spared
(Mitra, et al., 1997).
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The primary apoptosis-inducing factors have not been identified, although a possible
consideration is that impaired endothelial cell survival may be linked to loss of extracellular
matrix proteins (Dang, et al., 1999). Wu and co-workers demonstrated that one of twenty TTP
plasmas induced microvascular endothelial cell apoptosis in addition to platelet aggregation
(Wu, et al., 1999). Jimenez and co-workers reported an increase in the number of
microparticles in the blood from TTP patients and showed that TTP plasma causes
endothelial cell activation instead of apoptosis (Jimenez, et al., 2003).
Cytokines may have a role in the pathogenesis and upon exposure to TNF-α, endothelial cells
upregulate Fas expression (Laurence, et al., 1993). The upregulation of Fas is accompanied
by induction of cell cycle protein Cdc2 in dermal microvascular endothelial cells, however not
in large vessel endothelial cells (Laurence & Mitra, 1997). However, the induction of Fas by
TTP and HUS plasma may be irrelevant to apoptosis and merely reflect an activated cell
phenotype (Laurence & Mitra, 1997). Induction of endothelial cell apoptosis by TTP plasma
was confirmed by Wu and co-workers, however Fas did not appear to be implicated (Wu, et
al., 1999). Karpman and co-workers reported renal cortical cell apoptosis in children with
post-enterohepatic (D+) HUS (Karpman, et al., 1998).
Interleukin-6 was documented to be increased in the serum of 33 out of 35 children with HUS
and 2 out of 2 children with recurrent TTP (Karpman, et al., 1995). Karpman and co-workers
also documented raised TNF-α in the serum of 7 out of 35 HUS patients and in both children
with TTP (Karpman, et al., 1995).
In another study of children with HUS secondary to E. coli infection, Interleukin-6 (pro-
inflammatory) levels were increased and the concentration of Interleukin-10 (anti-
inflammatory) was also elevated to a lesser extent, and this suggests that an imbalance
between pro- and anti-inflammatory cytokines may be involved in the pathogenesis of
verotoxin-induced HUS (Litalien, et al., 1999). Normal human platelets were activated in vitro
by Interleukin-6 (Oleksowicz, et al., 1995). Wolf and co-workers reported that calpain is
involved in apoptosis-like events in washed human platelets, and although platelets contain
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pro-apoptotic caspases 3 and 9, calpain and not the caspases was found to promote
apoptosis-like events in platelets during platelet activation (Wolf, et al., 1999).
 Calpain and TTP
Calpain II comprise approximately 2% of total platelet protein and represents a major protein
component of platelets. Approximately 50% of platelet calpain is present in the cytosol and
approximately 50% is membrane associated (Schmaier, et al., 1990). In the presence of
calcium ions, calpain becomes membrane-associated and platelet activation by thrombin
results in presentation of calpain on the external platelet surface (Schmaier, et al., 1990). The
calcium ion concentration in resting platelets is not sufficient for calpain activation, however
the binding of an adhesive ligand to glycoprotein IIb/IIIa causes a rise in the calcium ion
concentration sufficient for calpain activation (Fox, et al., 1993).
An intracellular calpain inhibitor, Calpastat ®, inhibits thrombin-induced platelet alpha-granule
secretion and platelet aggregation (Croce, et al., 1999). In the sera of 15 patients with TTP,
during the acute phase and not remission, a calcium-dependent cysteine protease was
documented which was able to induce platelet aggregation (Murphy, Moore & Kelton, 1987).
This protease cleaved glycoprotein Ib (platelet receptor for VWF), and interfered with
ristocetin-induced platelet aggregation, and this was a previously reported finding for calpain
purified from human platelets (Yoshida, Weksler & Nachman, 1983).
Moore and colleagues documented that calpain from human platelets degraded VWF into
205kDa and 85kDa fragments with complete loss of large VWF multimers (Moore, Murphy &
Kelton, 1990). The calpain degraded VWF fragments were found to bind to glycoproteins
IIb/IIIa on the surface of activated platelets and cause platelet aggregation (Moore, Murphy &
Kelton, 1990).
Active calpain is associated with platelet microparticles in the plasma of TTP patients, which
protects calpain from plasma inhibitors such as α-2 macroglobulin and high molecular weight
kininogen (Kelton, et al., 1992). Plasma from normal subjects readily inhibits purified calpain,
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however microparticle-bound calpain from TTP patients is not inhibited by normal plasma
(Kelton, et al., 1992). The serum from normal control subjects lacks calpain-containing
microparticles (Kelton, et al., 1992).
Calpain activity was detected in bone marrow transplant-associated TTP, with 13% of grade 1
(subclinical), 38% of grade 2 (mild), 56% of grade 3 (moderate) and 100% of grade 4 (severe)
cases (Zeigler, et al., 1999). Whether calpain is associated with triggering the acute episode
of TTP or whether it reflects platelet aggregation by ULVWF multimers leading to release of
calpain, is still to be assessed (Furlan & Lämmle, 2001).
 Fibrinolysis
In TTP, at the site of microthrombi, the fibrinolytic activity of the vessel wall was shown to be
depressed (Kwaan, et al., 1979). A diminished tissue plasminogen activator activity and
protein C level and raised tissue plasminogen activator inhibitor with decreased fibrinolysis
has been demonstrated in TTP (Glas-Greenwalt, et al., 1985). Digestion of VWF has been
noted by various proteases such as calpain (Kunicki, Montgomery & Schullek, 1985),
cathepsin (Jelenska, et al., 1991) and plasmin (Lian, Nunez & Harkness, 1976; Hamilton, et
al., 1985). Fibrinolysis impairment and proteolysis of VWF independent of ADAMTS13 may
thus increase platelet aggregation and the stability of platelet-fibrin-VWF thrombi thereby
adding to the clinical picture and delay the recovery (Lian, 2005).
1. 5 Other associations with TTP
1. 5.1 Drugs
Many drugs have been associated with the development of TTP/HUS syndromes including
penicillin, quinine, mitomycin C, oral contraceptives and antiplatelet drugs such as ticlopidine
and clopidogrel (Wyrick-Glatzel, 2004). TTP may develop in this setting due to either an acute
immune-mediated response with drug dependent antibody formation or an insidious dose-
dependent toxic outcome (Wyrick-Glatzel, 2004).
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A severe reduction or complete absence of VWFCP was described in seven patients with
Ticlopidine associated TTP (Tsai, et al., 2000). Within 2 to 7 weeks of initiation of Ticlopidine
therapy, an inhibitor of VWFCP was documented in six of these patients. The VWFCP
deficiency resolved after Ticlopidine therapy had been discontinued and after plasmapheresis
had been commenced (Tsai, et al., 2000). VWFCP levels were undetectable in 2 patients with
clopidogrel-associated TTP during acute episodes and IgG inhibitors of VWFCP were present
(Bennet, et al., 2000).
1. 5.2 Post-bone marrow transplantation
Few studies have clarified the aetiology of post bone marrow transplantation and TTP
(Wyrick-Glatzel, 2004). In patients with bone marrow transplantation-associated TTP, normal
VWFCP activity was found (van der Plas, et al., 1999). Schriber & Herzig, reviewed cases of
post bone marrow transplant-associated TTP and revealed that fatal outcomes were
observed when: TTP developed within 120 days post-transplant, patients received
cyclosporine for graft-versus-host-disease, received an allogeneic transplant, had renal or
neurological abnormalities (Schriber & Herzig, 1997). A cytotoxic effect on endothelial cells
and an increase in VWF release is documented with the use of Cyclosporine (Wyrick-Glatzel,
2004). However many patients on clinical regimens that include immunosuppressive agents
post bone marrow transplant, do not develop TTP and other factors are likely to be
contributing to the development of TTP (Wyrick-Glatzel, 2004).
1. 5.3 Malignancies
Various malignancies are associated with coagulation disturbances and adenocarcinomas are
well associated with TTP/HUS, in particular gastric adenocarcinoma (Wyrick-Glatzel, 2004).
It is difficult to define the predisposing mechanism to TTP in malignancy especially since
various chemotherapeutic agents predispose to the development of TTP (Wyrick-Glatzel,
2004). Evaluating the degree of anaemia and thrombocytopenia relative to the particular
malignancy may assist in identifying and diagnosing TTP in this setting (Wyrick-Glatzel,
2004). Four patients with microangiopathic haemolytic anaemia secondary to metastasizing
neoplasia were found to have a normal or subnormal VWFCP activity, as opposed to patients
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with classical TTP where complete absence of VWFCP activity is noted (Furlan & Lämmle,
2001).
1.5.4 Autoimmune disease
Patients with autoimmune disease such as systemic lupus erythematosis, antiphospholipid
syndrome, polyarteritis nodosa and scleroderma, may develop TTP (Wyrick-Glatzel, 2004).
As patients with autoimmune disease may have multiorgan dysfunction, the pathological
features may be difficult to distinguish from that of TTP, thereby complicating the diagnosis
and initiation of effective treatment (Wyrick-Glatzel, 2004).
1. 6 Hereditary TTP
A number of mutations have been documented in the ADAMTS13 gene that affect the
synthesis or function of ADAMTS13 resulting in a congenital form of TTP (Furlan, et al., 1997;
Levy, et al., 2001). By contrast, VWF mutations have been identified that cause increased
susceptibility of VWF to ADAMTS13 proteolytic cleavage, which causes loss of high
molecular weight VWF multimers in plasma and defective binding of platelets. This is known
as type 2A Von Willebrand disease (Tsai, et al., 1997; Haberichter & Montgomery, 2006).
Levy and co-workers identified 12 different mutations in the ADAMTS13 gene which
accounted for 14 of 15 different disease alleles in families with hereditary TTP, and this study
convincingly related the ADAMTS13 gene to hereditary TTP (Levy, et al., 2001). As of
January 2005, 75 candidate mutations have been described in patients with hereditary TTP
(Levy, et al., 2001; Kokame, et al., 2002; Antoine, et al., 2003; Schneppenheim, et al., 2003;
Studt, et al., 2005; Motto, et al., 2002; Assink, et al., 2003; Savasan, et al., 2003; Bestetti, et
al., 2003; Veyradier, et al., 2004; Uchida, et al., 2004; Matsumoto, et al., 2004; Pimanda, et
al., 2004; Peyvandi, et al., 2004b; Kremer Hovinga, et al., 2004; Licht, et al., 2004; Snider, et
al., 2004; Tao, et al., 2004; Lämmle, Kremer Hovinga & Alberio, 2005). The majority of the
ADAMTS13 mutations are missense mutations, and this is followed by splice site, silent,
nonsense and frameshift mutations (Levy, et al., 2001; Zheng, Majerus & Sadler, 2002;
Kokame, et al., 2002). Most ADAMTS13 mutations have been identified in patients with
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familial TTP. However, it is uncertain whether these mutations contribute to acquired TTP,
which represent the majority of TTP cases (Shelat, Ai & Long Zheng, 2005).
ADAMTS13 mutations exhibit a heterogeneous phenotype as based on in vitro expression
studies, this depends on the effect on ADAMTS13 biosynthesis, secretion, and protease
bioactivity (Shelat, Ai & Long Zheng, 2005). The latter reflects the clinical heterogeneity seen
in patients with hereditary TTP, most of whom have compound heterozygous ADAMTS13
mutations (Shelat, Ai & Long Zheng, 2005). Affected patients are either homozygous carriers
or double heterozygotes of mutated alleles and the heterozygous parents of affected
individuals are found to be consistently asymptomatic (Lämmle, Kremer Hovinga & Alberio,
2005). Only approximately a third of described mutations have been expressed in mammalian
cells and most of the mutated proteins are not secreted (Kokame, et al., 2002; Uchida, et al.,
2004; Matsumoto, et al., 2004; Pimanda, et al., 2004; Schneppenheim, et al., 2004). Some of
the mutated proteins are secreted and these demonstrate deficient VWFCP activity (Uchida,
et al., 2004; Pimanda, et al., 2004).
Half of the patients with familial TTP experience acute episodes during childhood and half
during adulthood (Furlan & Lämmle, 2001). Patients presenting in adulthood may have acute
episodes associated with certain triggers such as pregnancy or infection (Furlan & Lämmle,
2001). Two pairs of sisters from two families with hereditary TTP, suffered their first episode
of TTP during pregnancy, whereas their brothers who were protease deficient remained
asymptomatic at greater than 35 years of age (Furlan & Lämmle, 2001).
Pregnancy is a known risk factor for TTP (Fuchs, et al., 1976; George, et al., 2003) and
increased VWF during pregnancy may be hypothesised as a triggering factor (Lämmle,
Kremer Hovinga & Alberio, 2005).
Hereditary TTP is assumed to be generally very rare. Nonetheless, this disease may have
been greatly misdiagnosed and underestimated (Lämmle, Kremer Hovinga & Alberio, 2005).
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In the Japanese population, a single nucleotide change in the ADAMTS13 gene that leads to
a Pro475Ser substitution, has an allele frequency of approximately 5% (Kokame, et al., 2002).
Normal secretion of a dysfunctional protease was shown with expression of this mutant and
the activity of the protease in a static assay was about 5% compared with wild-type
ADAMTS13 (Kokame, et al., 2002). It has however not been reported as to whether
homozygous carriers of the latter mutation are at risk for TTP or whether the presumably fairly
low ADAMTS13 activity is completely asymptomatic (Lämmle, Kremer Hovinga & Alberio,
2005).
A single nucleotide insertion in exon 29 (4143insA), is a disease-associated mutation reported
in two brothers from Sweden (Assink, et al., 2003), in 4 unrelated patients from Germany
(Schneppenheim, et al., 2003) and in one patient from Australia (Pimanda, et al., 2004).
An additional 7 patients with this mutation have been detected and a common founder
mutation was suggested on preliminary haplotype analysis, with the possibility of originating in
an ancestor near the Baltic sea region (Schneppenheim, et al., 2005).
As several patients with homozygous 4143insA mutation have been documented (apparently
non consanguinous), there may be many as yet undiagnosed homozygous individuals with
undiagnosed hereditary TTP and the medical profession should be aware of hereditary TTP
so as to institute timeous appropriate therapy and prophylaxis in these patients (Lämmle,
Kremer Hovinga & Alberio, 2005).
1.7 Differential diagnosis of TTP and related syndromes
Various different diseases may have similar features at presentation to TTP, such as HUS,
Thrombotic microangiopathy in pregnancy (including Pre-eclampsia / eclampsia and HELLP
syndrome: Haemolysis Elevated Liver enzymes and Low Platelets), autoimmune disorders or
DIC (Allford, et al., 2003; Wyrick-Glatzel, 2004).
Different clinical variants of TTP have been documented including congenital (ADAMTS13
mutations) or acquired. Acquired forms of TTP include acute idiopathic TTP (no identifiable
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precipitant), secondary TTP (to drugs, post bone marrow transplantation, in Systemic lupus
erythematosis, pregnancy, malignancy or infection including HIV) or intermittent TTP with
recurrent episodes of TTP at unpredictable time intervals (Allford, et al., 2003; Wyrick-
Glatzel, 2004; Yarranton & Machin, 2002; Furlan & Lämmle, 2001).
Drugs associated with TTP include the oral contraceptive pill, ticlopidine, clopidogrel,
cyclosporine and mitomycin C (Allford, et al., 2003; Tsai, et al., 2000; Bennet, et al., 2000;
Yarranton & Machin, 2002).
Congenital TTP has been associated with ADAMTS13 mutations and may present in infancy
or childhood (Upshaw-Schulman Syndrome) or adulthood (Congenital / familial chronic
relapsing TTP) (Wyrick–Glatzel, 2004). Acquired TTP may be associated with ADAMTS13
deficiencies due to autoantibodies (acquired transient or recurrent / intermittent TTP),
secondary to underlying diseases or idiopathic (Wyrick–Glatzel, 2004).
Clinical features and laboratory investigations are required to distinguish between the different
types of microangiopathic haemolysis. These conditions exhibit a spectrum of clinical and
laboratory parameters with respect to: neurological symptoms / signs, renal impairment, fever,
liver impairment, hypertension, haemolysis, thrombocytopenia and coagulopathy (Allford, et
al., 2003). Although overlap of clinical and laboratory parameters occurs and many conditions
are associated with a multitude of the above-mentioned features, some conditions are
associated with an emphasis of certain features such as renal dysfunction in HUS, liver
dysfunction in HELLP syndrome, coagulopathy in DIC and haemolysis and neurological
changes in TTP (Allford, et al., 2003; Wyrick-Glatzel, 2004).
Clinical and laboratory correlation is required to make the diagnosis of TTP. Although there is
no ‘absolute’ criteria for the diagnosis of TTP, severe ADAMTS13 deficiency with activity of
less than 5% together with severe thrombocytopenia, microangiopathic haemolysis, normal
INR and PTT and correlation with clinical and other laboratory parameters, defines a
diagnosis of TTP (Wyrick-Glatzel, 2004).
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As per recommendation by Allford and co-workers, TTP may be diagnosed and treatment
commenced if a patient present with microangiopathic haemolytic anaemia and
thrombocytopenia, in the absence of any other identifiable cause clinically (Allford, et al.,
2003). Routine clinical investigations recommended at presentation include: full blood count,
peripheral blood smear, DIC screen, LDH level, Direct Coomb’s test, urea and electrolytes,
liver function tests, and urine dipstick for protein. An underlying precipitant of TTP should be
considered and HIV and Hepatitis serology are recommended at presentation (Allford, et al.,
2003).
1.7.1 Thrombotic microangiopathy in pregnancy
The differential diagnosis of thrombotic microangiopathy (TMA) in pregnancy includes: TTP,
HUS, Pre-eclampsia / eclampsia / HELLP syndrome, DIC, acute fatty liver of pregnancy or
Systemic lupus erythematosis/antiphospholipid syndrome (Allford, et al., 2003).
Pre-eclampsia may produce a TMA with a variety of clinical pictures which may be similar to
TTP / HUS and the pentad of features of TTP can occur in pregnant women with pre-
eclampsia (Allford, et al., 2003). HELLP syndrome is usually diagnosed in the clinical setting
of pre-eclampsia with microangiopathic haemolytic anaemia and severe thrombocytopenia
and HELLP syndrome usually resolves within days following delivery (Wyrick-Glatzel, 2004).
Distinction between the various TMA in pregnancy remains based on history and physical
examination as well as routine laboratory investigations (Allford, et al., 2003).
The management of the different TMA in pregnancy is different and distinction between the
varying syndromes is essential to minimise maternal and foetal mortality (Weiner, 1987).
The clinical use of ADAMTS13 assays may bring clarity to the diagnosis and management of
TMA in pregnancy (Allford, et al., 2003). However this may be complicated by the knowledge
that ADAMTS13 levels are reduced in the last two trimesters of pregnancy (Mannucci, et al.,
2001) with a concomitant increase in VWF (George, Vesely & Terrell, 2004).
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1.7.2 Acute Idiopathic TTP
Acute Idiopathic TTP may be difficult to diagnose clinically and relapse is considered common
and frequent in these cases (Wyrick-Glatzel, 2004). Many cases are due to autoantibody
formation which mediates a severe ADAMTS13 deficiency (Wyrick-Glatzel, 2004).
These cases often demonstrate remission which is associated with absence of the
autoantibody and normal ADAMTS13 levels and reappearance of the autoantibody often
precedes clinical relapse with subsequent severe ADAMTS13 deficiency and ULVWF
multimers are documented in some cases (Wyrick-Glatzel, 2004). Standard plasma exchange
with replacement of fresh frozen plasma (FFP) is efficacious in these patients and this is
thought to be due to this therapy removing the inhibitory autoantibody (plasma exchange) and
supplying the ADAMTS13 protease (FFP) (Wyrick-Glatzel, 2004).
1.7.3 Haemolytic Uraemic Syndrome
Haemolytic Uraemic Syndrome (HUS) is characterised by the presence of microangiopathic
haemolytic anaemia with thrombocytopenia and renal failure (Allford, et al., 2003). HUS may
be associated with more extensive multiorgan disease, including neurological complications,
liver dysfunction, enterocolitis, pancreatic and cardiac problems (Siegler, 1994). There is
clinical overlap with TTP in such patients, especially when there are associated neurological
problems (Siegler, 1994). It is important to distinguish between TTP and HUS, where
possible, as the most appropriate clinical management can then be ascertained (Allford, et al.,
2003).
HUS is a primarily renal microangiopathy which is associated with glomerular microvascular
platelet aggregation and formation of fibrin polymers (Nolasco, et al., 2005). The
consequences include microangiopathic haemolytic anaemia, thrombocytopenia, acute renal
failure and sometimes dysfunction of other organs may occur (Moake, 2002; Nolasco, et al.,
2005; Tarr, Gordon & Chandler, 2005).
HUS often occurs after an episode of haemorrhagic colitis or diarrhoea (Nolasco, et al.,
2005). Microbes involved include Shigella dysenteriae serotype 1 or more often, specific
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enterohaemorrhagic serotypes of Escherichia coli (O157:H7) (Cleary, 1988; Karmali, et al.,
1985; Banatvala, et al., 2001; Brett, et al., 2003; Misselwitz, et al., 2003). The exotoxins
produced by these bacteria include the Shiga toxin (Stx: produced by S. dysenteriae) or Stx-1
and Stx-2 (produced by enterohaemorrhagic E. coli subtypes) (Brett, et al., 2003; Misselwitz,
et al., 2003; Matussek, et al., 2003; Eklund, Leino & Siitonen, 2002).
Various clinical subtypes of HUS are present including the Epidemic form (D+) associated with
a prodromal illness of diarrhoea (bloody) and the Sporadic form (D-) (Allford, et al., 2003). In
D+ HUS, verotoxin producing organisms are identified in 90% and in the D- HUS, verotoxin
producing organisms are identified in only 2-7% and other non-verotoxin infections may be
present such as HIV, Streptococcus pneumoniae, Aeromonas hydrophilia, Campylobacter
upsaliensis, Capnocytophaga canimorsus and Cytomegalovirus (Allford, et al., 2003).
A reduced level of the third component of the complement system (C3) has been documented
in the serum of patients with familial and atypical HUS (Ohali, et al., 1998; Noris, et al., 1999).
The decreased serum concentration of C3 may be related to a functional abnormality or
deficiency of complement factor H, an important plasma regulator of the alternative
complement activation pathway (Pichette, et al., 1994; Warwicker, et al., 1998; Rougier, et al.,
1998; Ying, et al., 1999). Therefore complement-mediated endothelial cell activation and
subsequent release of ULVWF multimers may be hypothesised as a cause for familial and
sporadic HUS (Furlan & Lämmle, 2001).
Remuzzi and co-workers, suggest that ADAMTS13 deficiency does not distinguish TTP (at
least the recurrent and familial forms) from HUS and low values of ADAMTS13 may not be
specific for TTP (Remuzzi, et al., 2002). Remuzzi and co-workers challenge the statement by
Furlan and co-workers, that a single laboratory test for ADAMTS13 activity may be able to
distinguish TTP from HUS (Remuzzi, et al., 2002; Furlan, et al., 1998; Moake, 1998) and that
the protease defect should not be narrowed to specific subtypes of thrombotic
microangiopathies (Remuzzi, et al., 2002). The issue of whether ADAMTS13 activity may
enable clinicians to distinguish TTP from HUS remains controversial (Remuzzi, et al., 2002).
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It has been proposed that TTP and HUS are merely different expressions of the same
disease process (Furlan & Lämmle, 2001; Remuzzi & Garella, 1987; Ruggenenti, Remuzzi &
Rossi, 1991).Furlan and co-workers recommend that a new classification should replace the
inappropriate clinical discrimination between TTP and HUS (Furlan & Lämmle, 2001).
TTP/HUS can be viewed as a collection of clinical and laboratory findings which occur due to
a variety of unrelated causes (Furlan & Lämmle, 2001). In all forms of TMA, the primary event
appears to involve the injury, death or activation of microvascular endothelial cells and the
term TTP is preferred in adults with predominant neurological abnormality and cases with
predominant glomerular dysfunction, occurring mainly in childhood, termed as HUS (Furlan &
Lämmle, 2001).
Drummond, suggested a new classification for HUS, based on insights accumulated in the
early 1980’s: classic form representing cases of D+ HUS in children, post-infectious form
(following certain bacteria or viruses), immune-associated form (activation of alternative
complement pathway), forms associated with other illnesses or precipitants or forms
associated with pregnancy or the oral contraceptive (Drummond, 1985).
Remuzzi & Garella, proposed a modified version of this scheme: Infantile and childhood
HUS/TTP (usually characterised by a diarrhoeal prodrome but not associated with a
recognised infection), Hereditary and recurrent HUS/TTP (in children and adults), post-
infectious HUS/TTP (occurs at any age, caused by E. coli, Shigella, Salmonella or
Streptococcus infection), HUS/TTP accompanying systemic disease, HUS/TTP associated
with pregnancy, contraceptives, cyclosporin A or antineoplastic drugs (Remuzzi & Garella,
1987).
Furlan & Lämmle, propose that a new classification should be established based on further
advances and this should recognise the differences between congenital and acquired (due to
autoantibodies) deficiencies of ADAMTS13 and secondary precipitating causes of TTP (such
as infection, pregnancy, drugs, autoimmune disease) (Furlan & Lämmle, 2001).
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1.8 Treatment of TTP
Preceding the use of plasma exchange, the mortality of patients with TTP was greater than
90% (Wyrick-Glatzel, 2004). In 1977, Byrnes & Khurana, reported that recurrence of TTP
could be prevented by infusion of Fresh Frozen Plasma (FFP) or cryosupernatant without the
associated use of plasma exchange (Byrnes & Khurana, 1977; Stefano, et al., 2004).
Normal ADAMTS13 activity was documented in FFP, cryosupernatant (which lacks the larger
VWF multimers) and solvent/detergent-treated plasma (SD-FFP) and these components were
shown to be effective in the treatment of congenital relapsing TTP (Moake, 2004). Although
TTP patients have been managed by plasma infusion with or without plasma exchange, the
Canadian Apheresis group demonstrated that plasma exchange was more effective than
plasma infusion in the therapeutic management of TTP (Rock, et al., 1991).
Guidelines for the management of thrombotic microangiopathy have been proposed (Allford,
et al., 2003).
Many studies have noted that FFP, cryosupernatant and SD-FFP contain biologically active
ADAMTS13 (Wyrick-Glatzel, 2004). Plasma exchange is considered efficacious in the
treatment of TTP with a significant decrease in the mortality rate to between 10% and 20%
(Wyrick-Glatzel, 2004). The therapeutic effect of plasma exchange in the treatment of TTP is
attributed to removing ADAMTS-13 neutralising autoantibodies and restoration of ADAMTS13
activity by replacing the enzyme (Böhm, et al., 2005).
Corticosteroids have also frequently been used in addition (Bell, et al., 1991). In conjunction
with plasma exchange, corticosteroids may be used if a response is not seen with normal
plasma exchange (Wyrick-Glatzel, 2004). As many patients may have auto-antibody induced
ADAMTS13 deficiency, plasma exchange may remove autoantibodies, FFP replace the
deficient enzyme and corticosteroids may suppress autoantibody formation (Lämmle, Kremer
Hovinga & Alberio, 2005). Cryosupernatant which lacks the larger multimers of VWF, has
been used instead of plasma exchange as a replacement fluid and seemed to be more
effective if compared to an historical control group in which FFP was used (Rock, et al.,
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1996). Although subsequent randomised studies have not substantiated the latter finding
(Zeigler, et al., 2001; Lämmle, Kremer Hovinga & Alberio, 2005).
Splenectomy performed in remission, after relapse may be effective and may relate to the
elimination of B-cells which are autoantibody producing (Lämmle, Kremer Hovinga & Alberio,
2005). Several patients with autoimmune-mediated ADAMTS13 deficiency and relapsing
TTP, have been treated with a monoclonal anti-CD20 antibody, Rituximab TM, and successful
short-term results have been reported (Chemnitz, et al., 2002; Gutterman, Kloster & Tsai,
2002; Tsai, et al., 2003; Zheng, et al., 2003b; Ahmad, et al., 2004; Sallah, et al., 2004).
Prospective trials are required to assess whether Rituximab TM has a long-term advantage
over the use of corticosteroids, other immunosuppressive therapy or splenectomy (Lämmle,
Kremer Hovinga & Alberio, 2005).
Hereditary TTP due to double heterozygous or homozygous ADAMTS13 gene defects may
be treated with FFP infusion (Furlan & Lämmle, 2001). Relapses in congenital TTP patients
may be prevented by regular infusion of FFP every 2 to 3 weeks (Barbot, et al., 2001).
Severe thrombocytopenia with a platelet count below 20x10^9/l together with
microangiopathic haemolytic anaemia in the absence of another underlying cause, is
considered sufficient for the diagnosis of TTP and to commence plasma exchange as
standard therapy (Wyrick-Glatzel, 2004). Plasma exchange should ideally be commenced
within the first 24 hours of presentation and therapy should continue for a few days after a
normal platelet count, stable haemoglobin level, normal LDH level and normal neurologic
findings have been documented, until remission has been achieved (Wyrick-Glatzel, 2004).
When plasma exchange cannot be performed then the use of FFP is recommended to bridge
the gap (Wyrick-Glatzel, 2004). The use of platelet infusion is contraindicated in the setting of
TTP, numerous studies suggest higher morbidity and mortality rates when platelet
concentrates are administered in TTP (Wyrick-Glatzel, 2004). A cohort of patients who
received platelet concentrates during the course of therapy for TTP, post-mortem revealed
extensive cerebral nervous system platelet aggregates (Nabban, et al., 2003).
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Although plasma exchange is considered generally safe, approximately 10% of patients
receiving plasma exchange may experience adverse reactions such as central venous
catheter thrombosis, allergic reactions, pneumothorax, haemorrhage, infection or hypotension
(Wyrick-Glatzel, 2004). Infusion of plasma containing products may result in Transfusion-
related acute lung injury (TRALI) which is estimated to have an incidence of 0.02% to 0.03%
per transfused plasma containing unit (Stefano, et al., 2004). When evaluating the therapeutic
management of patients with thrombotic microangiopathy, these risks should be taken into
consideration (Wyrick-Glatzel, 2004).
Novitsky and co-workers report that in patients with HIV, TTP is highly responsive to plasma
infusion (Novitsky, et al., 2005). In HIV positive patients with TTP (n=21), Novitsky and co-
workers, report that the disease presentation parameters reflect a more advanced disease
stage compared to an HIV negative cohort (n=23), however the HIV positive patients had a
significantly better and faster response to plasma infusion (Novitsky, et al., 2005). Novitsky
and co-workers recommend, that where apheresis is not available, adequate FFP infusion
should be commenced without delay and, that future prospective trials should assess whether
apheresis is superior to FFP infusion in individuals with HIV-related TTP (Novitsky, et al.,
2005).
At least for all patients with idiopathic TTP, plasma exchange therapy with FFP replacement
remains crucial, even in the absence of a severe ADAMTS13 deficiency (Lämmle, Kremer
Hovinga & Alberio, 2005). TTP patients who are plasma refractory or relapsing patients may
be treated with more rigorous plasma exchange regimens, such as twice daily (Lämmle,
Kremer Hovinga & Alberio, 2005).
1.9 Von Willebrand Factor Cleaving Protease / ADAMTS13
Levy and co-workers performed a genome-wide linkage analysis in patients with congenital
TTP and the responsible genetic locus was mapped to chromosome 9q34 (Levy, et al., 2001).
ADAMTS13 was identified as a new member of the ADAMTS family of zinc metalloproteases
and deficiency of ADAMTS13 (required for proteolysis of VWF) was documented as the
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molecular mechanism responsible for the development of TTP (Levy, et al., 2001). The data
from a number of studies suggests that ADAMTS13 is the VWFCP itself (Levy, et al., 2001;
Moake, et al., 1982; Tsai, 1996; Furlan, Robles & Lämmle, 1996; Tsai & Lian, 1998; Furlan, et
al., 1998). Reported purification and sequence analysis of the amino-terminal amino acids of
human VWFCP confirmed the identity of ADAMTS13 as the VWFCP (Fujikawa, et al., 2001;
Gerritsen, et al., 2001).
1.9.1 Molecular biology of ADAMTS13
ADAMTS13 is a zinc-binding metalloproteinase with 1427 amino acids which forms a
multidomain structure (Fujimura, 2005). The main site of synthesis of ADAMTS13 is in the
liver (by hepatic stellate cells) and it is also synthesised in vascular endothelial cells (Shelat,
Ai & Long Zheng, 2005). The cleavage of VWF into 140kDa and 176kDa fragments in normal
plasma, not caused by plasmin or cathepsin, was first described by Berkowitz and co-workers
in 1987 (Berkowitz, et al., 1987). The cleavage was shown to be at the tyrosine 1605-
methionine 1606 bond (Dent, et al., 1990).
In 1996, a plasma metalloprotease was described that cleaved VWF at the same bond into
140kDa and 176kDa fragments under reducing conditions or into 200kDa and 350kDa
fragments under non-reducing conditions (Tsai, et al., 1996; Furlan, Robles & Lämmle, 1996).
ADAMTS13 comprises a short propeptide, a metalloprotease domain (typical reprolysin-like),
a disintegrin-like domain, first Thrombospondin type 1 (TSP1) repeat, a Cys-rich domain and
a spacer domain. Seven more TSP1 repeats and two CUB domains are present in the
carboxyl terminus of ADAMTS13 (Shelat, Ai & Long Zheng, 2005).
The metalloprotease domain of ADAMTS13 has three Histidine residues that co-ordinate
essential Zinc or Calcium binding (Zheng, et al., 2001). Also present in the metalloprotease
domain is a conserved Met249 which forms a Met-turn and the residues forming a predicted
Calcium co-ordination site (Glu 83, Asp173, Cys281, Asp284) (Zheng, et al., 2001).
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Refer to Figure 2 for a schematic representation of the ADAMTS13 protein.
Figure 2. Schematic depiction of the ADAMTS13 protein. Adapted from: Lämmle, Kremer-
Hovinga & Alberio, 2005. Thrombotic Thrombocytopenic Purpura. J Thromb Haemost, vol. 3,
pp. 1665.
All of the proximal carboxyl terminal domains of ADAMTS13 are required for recognition and
cleavage of VWF (Ai, et al., 2005). VWF73 (D1659-R1668) has been demonstrated to be the
essential and minimal peptide region of VWF which is recognised and cleaved by ADAMTS13
(Kokame, et al., 2003). Proteolysis of VWF and VWF73 by various ADAMTS13 mutants
revealed that each of the proximal carboxyl terminal domains of ADAMTS13 not only
participate in substrate recognition but also act co-operatively to confer efficient binding (Ai, et
al., 2005).
The affinity of ADAMTS13 binding to VWF73 is approximately three times higher than to VWF
which suggests that the domains surrounding the central A2 subunit of VWF are involved in
negative regulation of the ADAMTS13-VWF interaction (Majerus, et al., 2003; Ai, et al., 2005).
Full-length ADAMTS13 can bind to VWF with stoichiometry of 1:2, with equilibrium reached
at ~2 hours and a half-life of dissociation of ~4 hours (Ai, et al., 2005; Majerus, et al., 2003).
The ADAMTS13 spacer domain has a significant contribution to ADAMTS13-VWF interaction
(Majerus, et al., 2003).
Factors modulating VWF cleavage by ADAMTS13 include: shear stress, platelets or platelet
glycoprotein-1bα (GP1bα), inflammatory cytokines such as interleukin 6, heparin sulphate or
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sodium chloride (Shelat, Ai & Long Zheng, 2005). The Tyr1605-Met1606 bond in the A2
domain of VWF is buried within the core β sheet of the structure (Jenkins, Pasi & Perkins,
1998). Shear force, denaturing agents or binding of VWF to platelets, exposes the
ADAMTS13 binding and cleavage site on VWF, thereby enhancing VWF cleavage by
ADAMTS13 (Furlan, Robles & Lämmle, 1996; Tsai, 1996; Tsai & Lian, 1998). However, the
ADAMTS13 binding site on VWF is not fully exposed in the presence of denaturing agents
and the A1 domain of VWF may block access of ADAMTS13 to the cleavage site (Nishio, et
al., 2004). The interaction of VWF with platelet glycoprotein 1bα or unfractionated heparin,
removes this blockage (Nishio, et al., 2004).
VWF is a large multimeric protein synthesised in endothelial cells and megakaryocytes as a
precursor containing a signal peptide and propeptide (Wagner, 1989). Endothelial VWF may
be secreted through regulatory and constitutive pathways and VWF transported through the
regulated pathway is first stored in the Weibel Palade body (Wagner, 1993). VWF mediates
platelet adhesion to the subendothelium and platelet aggregation through binding platelet
glycoprotein Ib under conditions of high shear stress (Ruggeri, Dent & Salvidar, 1999).
Subsequent to secretion, multimeric VWF is gradually but continuously cleaved to smaller
multimers in the circulation (Tsai, 1989; Dent, et al., 1990; Dent, Galbusera & Ruggeri, 1991;
Furlan, et al., 1993). VWF is rapidly cleaved by ADAMTS13 under conditions of high shear
stress (which probably exposes the cleavage site), however is resistant to cleavage under
static conditions (Haberichter & Montgomery, 2006). In the normal degradation process of
VWF multimers, the role of ADAMTS13 is not as yet completely distinct (Haberichter &
Montgomery, 2006).
Under conditions of high fluid shear stress, VWF unfolds and becomes more adhesive, this is
possibly related to tensile force causing unfolding of the A2 domain of VWF and exposure of
the otherwise hidden Tyr1605-Met1606 cleavage site which is then accessible to ADAMTS13
for cleavage (Tsai, 1996; Goto, et al., 1998; Siedlecki, et al., 1996).
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VWF cleavage by ADAMTS13 is therefore favoured by the relatively high hydrodynamic
forces generated when platelets adhere to VWF on endothelial cells (Dong, et al., 2003) or in
platelet aggregation (Ajzenberg, et al., 2002; Yagi, et al., 2001). ADAMTS13 binds to the A1
and A3 domains of VWF thereby docking the enzyme in close proximity to the A2 domain to
facilitate VWF cleavage (Lopez & Dong, 2004). Larger VWF multimers possess higher affinity
receptors for platelet receptors glycoprotein Ib and glycoprotein IIb/IIIa (Federici, et al., 1989),
are unfolded more easily under conditions of high shear stress (Tsai 2002) and extend longer
so as to bind more platelets (Lian, 2005). High shear stress is observed particularly in
pathologically narrowed arteries and arterioles and the unfolded VWF which is unchecked in
TTP, easily binds platelets and the platelet aggregates formed, sludge in the arterioles and
capillaries as platelet thrombi (Lian, 2005).
Approximately 90% of VWF in a resting solution is present in the form of linear polymers
coiled upon themselves in a ‘ball of yarn’ (globular) form, as shown with electron microscopy
(Slayter, et al., 1985). VWF undergoes a conceivably shear-induced conformational transition
from a globular state to an extended chain conformation thereby exposing intramolecular
globular domains (Siedlecki, et al., 1996). It has been shown that the binding of platelet
glycoprotein Ibα the A1 domain of VWF, stimulates the adjacent A2 domain cleavage by
ADAMTS13 (Nishio, et al., 2004).
ADAMTS13 functions to regulate the adhesive action of VWF and ADAMTS13 and shear
stress regulate VWF activity (Tsai, 2003). VWF mediates initial platelet adhesion to damaged
subendothelium in conditions of high shear stress (Furlan & Lämmle, 2001). Brief exposure of
VWF to conditions of high shear stress increases the ability of VWF to support platelet
aggregation (Tsai, 2002). The conformational response of VWF is size dependent with only
the large multimers demonstrating increased activity in response to conditions of high shear
stress (Tsai, 2002).
Refer to Figure 3 for a diagrammatic representation of a model for the pathogenesis of TTP
with representation of the globular versus the linear from of ULVWF multimers.
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Figure 3. Model for the pathogenesis of TTP. Adapted from: Yarranton & Machin, 2002.
Thrombotic Thrombocytopenic Purpura: New Approaches to Diagnosis and Management.
Blood Therapies in Medicine, Vol 2 (3), pp. 86. A reflects normal processing, ULVWF
(Ultralarge VWF) multimers are secreted by endothelial cells and circulate in globular
formation in large vessels. Under conditions of high shear stress however, the ULVWF
multimers unfold to a linear form and expose cleavage sites for VWFCP and platelet binding
sites. Less biologically active smaller VWF fragments are generated (ULVWF multimers
cleaved at Met-842 and Tyr-843 bond). B reflects acquired TTP, where an autoantibody
(Immunoglobulin G) inactivates VWFCP. Under conditions of high shear stress there is no
processing of ULVWF multimers which then readily bind both platelets and the endothelium.
Small vessel occlusion by platelet-rich thrombi then occurs.
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1.9.2 Regulation of ADAMTS13 activity
The cleavage of ULVWF multimers is inhibited by Interleukin-6 under flow (Bernardo, et al.,
2004) suggesting a possible link between inflammation and coagulation (Shelat, Ai & Long
Zheng, 2005). Inflammatory cytokines such as Interleukin-8 and Tumour Necrosis Factor-
alpha may stimulate the release of ULVWF multimers (Bernardo, et al., 2004). Chloride ions
(De Cristofaro, et al., 2005) and haemoglobin (Studt, et al., 2005) may also regulate the
ADAMTS13-VWF interaction. Data by Crawley and co-workers, suggests that ADAMTS13
activity is regulated at the site of thrombus formation by Thrombin, Factor Xa and Plasmin, by
proteolytic cleavage (Crawley, et al., 2005). As described by Crawley and co-workers,
ADAMTS13 circulates as an active enzyme when secreted into plasma. VWF binds to
exposed collagen at sites of endothelial injury and then VWF unfolds in response to shear
stress, thereby facilitating platelet tethering which is required for platelet plug formation
(Crawley, et al., 2005). If ADAMTS13 were to act unchecked, its VWFCP activity would
predictably oppose the crucial tethering of platelets to VWF (Crawley, et al., 2005). The
proposed regulatory mechanism of Crawley and co-workers, suggests that ADAMTS13 could
be proteolytically inactivated by thrombin at sites of vascular injury, thereby promoting a
prothrombotic milieu at a site of vascular perturbation (by inhibiting ADAMTS13, VWF
molecules remain intact promoting coagulation) (Crawley, et al., 2005).
In initial platelet plug formation, platelets adhere to both VWF and collagen and the tight
association with collagen may assist in the initial resistance of VWF cleavage by ADAMTS13
with subsequent platelet release. However the association of platelets with collagen will be
more remote in subsequent layers of the platelet plug (Crawley, et al., 2005).
Imaging of in vivo thrombus formation revealed “blebbing-off” of platelets tethered from the
back of the developing thrombus prior to thrombin generation or the deposition of fibrin
(Falati, et al., 2002). The latter observation may be explained by the uninhibited action of
ADAMTS13 on VWF-bound platelets and highlights the necessity of inhibition of ADAMTS13
at a site of endothelial damage (Crawley, et al., 2005).
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Multiple physiological roles and substrates are noted for the Thrombin molecule (Chang,
1985; Di Cera, 2003). After coagulation has been initiated Thrombin has a procoagulant role
by cleaving Fibrinogen, by feeding back positively on the coagulation cascade and by
activating tethered platelets (Narayanan, 1999).
Thrombin activates clotting factors V, VIII, X and XI (Di Cera, 2003). A novel procoagulant
function of Thrombin is described by Crawley and co-workers, which involves ADAMTS13
inactivation which promotes thrombus growth (by preventing cleavage of VWF) (Crawley, et
al., 2005).
There has been possible implication of a role of ADAMTS13 deficiency in the pathogenesis of
certain thrombotic disorders (Böhm, et al., 2003a; Gao, et al., 2003). However, Crawley and
co-workers suggest that during the course of a thrombotic event, increased thrombin-
dependent inactivation of ADAMTS13 may occur and result in reduced ADAMTS13 levels.
Therefore additional studies would be of value in determining whether a partial ADAMTS13
deficiency is a primary cause or a consequence of thrombosis (Crawley, et al., 2005).
There is physiological modulation of the activity and specificity of thrombin by cofactors which
compete for exosite binding, thereby directing either a procoagulant or anticoagulant effect of
thrombin (Philippou, et al., 2003). When thrombin binds thrombomodulin on intact
endothelium (Thrombin exosite 1 occupied with Thrombomodulin), it has an anticoagulant
effect by activating the Protein C pathway, thereby restricting the procoagulant effects (such
as fibrinogen cleavage) to the site of vascular injury (Sadler, 1997; Ye, Esmon & Johnson,
1993).
Crawley and co-workers documented that when Thrombin was preincubated with
Thrombomodulin, its ability to proteolyse ADAMTS13 was significantly reduced and Thrombin
exosite 1 may therefore be implicated in the binding of ADAMTS13 (Crawley, et al., 2005).
Crawley and co-workers noted that Plasmin cleaved ADAMTS13 at a faster rate than
Thrombin. Plasmin mediates physiological fibrinolysis and is generated subsequent to
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thrombin-dependent fibrin deposition (Collen, 1999). As ADAMTS13 is cleaved at low plasmin
concentrations, this may suggest a physiologically important role of modulating ADAMTS13
activity at a site of haemostatic plug formation (Crawley, et al., 2005). Plasmin activity is
associated with post-injury vessel repair and as there may be a possible role for VWF in
tissue repair, the cleavage of ADAMTS13 by Plasmin would prevent cleavage of VWF
(Crawley, et al., 2005). Although Plasmin activates several prometalloproteinases, it
inactivates ADAMTS13 (Murphy, et al., 1999).
The data from Crawley and co-workers suggests that Thrombin-dependent inactivation of
ADAMTS13 may be specifically localised to the site of haemostatic plug formation. The
ADAMTS13 activity does occur when Thrombin is bound to Thrombomodulin which
constitutes an anticoagulant milieu where ADAMTS13 activity (cleavage of VWF) assists in
limiting platelet aggregation from spreading beyond the site of injury (Crawley, et al., 2005).
On damaged endothelium, the absence of Thrombomodulin allows Thrombin to bind
(proposed via exosite 1), and inactivate ADAMTS13, thereby facilitating the initial platelet
adhesion process (Fujimura, 2005).
Platelet adhesion to a site of vascular injury occurs as a two-step process with initial platelet
rolling which is mediated by a transient interaction between platelet glycoprotein 1b-IX-V and
surface immobilised VWF (which binds exposed collagen at sites of endothelial injury).
Subsequently firm platelet adhesion occurs following the binding of platelet integrin αIIbβ3
(Savage, Salvidar & Ruggeri, 1996).
Matsui and co-workers analysed thrombus formation in vitro on a collagen surface under
conditions of high sheer stress and the interaction of VWF and fibrinogen (Matsui, et al.,
2002). This study revealed that during initial thrombus formation, platelet thrombi are
composed of VWF and platelet-derived fibrinogen accumulates mainly inside the growing
thrombus thereby serving as a core adhesive ligand, however the thrombus surface exposed
to blood flow, is constantly occupied with VWF (Matsui, et al., 2002).
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The ability of VWF to bind thrombi that are forming depends on its multimeric size (with
multimers ranging into millions of daltons). The multimeric state of VWF is regulated by both
ADAMTS13 cleavage in the circulation and the number of N-terminal intersubunit disulfide
bonds formed in the Golgi complex (Yarranton & Machin, 2002; Sadler, et al., 2004).
ADAMTS13 cleaves ULVWF multimers which are hyperactive, to less active smaller forms
(Bernardo, et al., 2004).
VWF is synthesised and stored in the Weibel Palade bodies of endothelial cells and the alpha
granules of megakaryocytes and platelets (Wagner & Marder, 1983; Ruggeri & Ware, 1992;
Sadler, 1998). The main source of plasma VWF is endothelial cells, which release VWF
multimers on stimulation as well as constitutively (Sadler, 1998; Tsai, et al., 1991). VWF
forms released upon stimulation are usually rich in the hyperactive ultralarge multimers (Tsai,
et al., 1991; Moake, et al., 1982). In the absence of any modulators, the ultralarge multimers
form high strength bonds with platelet glycoprotein 1b-IX-V (Arya, et al., 2002; Moake &
Chow, 1998; Federici, et al., 1989).
Dong and co-workers showed that the ULVWF multimers secreted from endothelial cells are
anchored to the cell surface and form long string-like structures which can induce platelet
adhesion and aggregation (Dong, et al., 2002). In vitro, the ULVWF multimer strings are
cleaved at more than 1000 fold faster than under static conditions which may imply that in
vivo the ULVWF multimer processing occurs on or near the surface of endothelial cells
(Bernardo, et al., 2004).
The proteolytic cleavage of ULVWF multimers is in a constant state of homeostatic balance
between the proteolytic capacity of ADAMTS13 and the amount of ULVWF multimers
released from the endothelium (Bernardo, et al., 2004). Pathological conditions may arise
from disruptions of this balance and range from bleeding to thrombosis. Sustained deficiency
of ADAMTS13 may be congenital or acquired and results in microangiopathic haemolysis,
such as TTP (Moake, 2002), whereas bleeding disorders such as type 2A Von Willebrand
disease is associated with increased proteolysis (Batlle, et al., 1994).
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The ULVWF / ADAMTS13 control mechanism may also be affected by rapid or excessive
release of ULVWF multimers or by a transient inhibition of ADAMTS13 mediated cleavage of
ULVWF multimers (Bernardo, et al., 2004). Reported increased levels of VWF occur in a
variety of disease entities such as autoimmune diseases (McEntegart, et al., 2001; Porta,
Caporali & Montecucco, 1999), infections both bacterial and viral (Kayal, et al., 1998;
Tzavara, et al., 1997), trauma (Siemiatkowski, et al., 2000) and peripheral arterial and
coronary disease (Jager, et al., 1999, Nielsen, Siegbahn & Swahn, 2000). In these conditions,
Inflammation may be the shared cause for release of endothelial cell derived ULVWF
multimers which may lead to a consumptive deficiency of ADAMTS13 (Bernardo, et al.,
2004).
1.10 Overview of causes of thrombocytopenia in HIV
One of the most common haematological manifestations of HIV infection is thrombocytopenia
which may be multifactorial in nature, however it is frequently attributed to the direct effects of
HIV (Blazes & Decker, 2004; Sloand, 2005). Thrombocytopenia is also frequently due to
immune-related thrombocytopenia (Blazes & Decker, 2004; Miller, et al., 2005). Other causes
of thrombocytopenia to consider in HIV include: HIV associated decreased production (direct
infection of megakaryocytes), drug-related causes, hypersplenism, marrow infiltration or other
infections including opportunistic infections (Geethesh, et al., 2005; Sloand, 2005). TTP, a
form of thrombotic microangiopathy (TMA), is another cause for thrombocytopenia. Although
TMA is a less common entity than other causes for thrombocytopenia, it is a serious and life-
threatening entity and clinicians must be aware of the diagnostic and therapeutic importance
(Blazes & Decker, 2004).
TTP is associated with a pentad of features including microangiopathic haemolytic anaemia,
thrombocytopenia, fever, neurological dysfunction and renal impairment.
The differential diagnosis of thrombocytopenia, anaemia and neurological dysfunction is
broad in patients with Acquired ImmunoDeficiency Syndrome (AIDS) (Cines, Konkle & Furlan,
2000). DIC is a form of microangiopathic haemolysis which must be distinguished from TTP
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or HUS and a DIC screen is of value in assessing for the presence of a consumptive
coagulopathy.
1.11 TTP and HIV
Literature for HIV-associated TMA is limited. TTP may be the presenting clinical manifestation
of HIV infection, although the majority of cases occur in the context of AIDS (Hymes &
Karpatkin, 1997). The outcome and survival of TTP in the setting of HIV may be related to the
stage of HIV infection and severity of immunosuppression at which TMA occurs (Bell, Chulay
& Feinberg, 1997; Blazes & Decker, 2004; Hymes & Karpatkin, 1997; Ripamonti, et al., 1996).
Early diagnosis and treatment of TTP is imperative for survival (Cines, Konkle & Furlan, 2000;
Rock, et al., 2000).
Blazes and Decker report that the CD4 count at the time of illness appears to affect duration
of response to therapy (patients with CD4 counts greater than 100cells/mm3 had a mean
survival of 2 years, whereas those with CD4 counts less than 100cells/ mm3 had mean
survivals of 6 months) (Blazes & Decker, 2004).
A study by Tamkus and co-workers, showed that if plasma exchange is instituted early,
clinical remission may be seen in half of HIV positive patients with TMA, although in-patient
mortality reached almost 50% in this study (Tamkus, et al., 2006). Early diagnosis and
treatment with plasma exchange may be lifesaving in TMA, but the overall prognosis in
patients with advanced HIV (with low CD4 counts) who develop TMA is generally considered
poor (Bell, Chulay & Feinberg, 1997; Blazes & Decker, 2004; Gadallah, et al., 1996;
Gervasoni, et al., 2002). Bell and co-workers identified a group of HIV positive patients with a
TMA-like syndrome who when compared with previously reported patients with HIV-
associated TMA, had lower CD4 counts, more frequent opportunistic infections, less severe
thrombocyopenia, less frequent neurological abnormalities and a poor response to therapy
appropriate for TMA (Bell, Chulay & Feinberg, 1997) . Potential risk factors for the
development of a TMA-like syndrome identified by Bell and co-workers include the use of high
dose valacyclovir and the relative risk may be increased in patients receiving fluconazole
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(Bell, Chulay & Feinberg, 1997). Bell and co-workers suggest that the short term prognosis of
patients with a TMA-like syndrome seems to be better in patients with neurological
manifestations, possibly because such patients are more likely to have classical TMA that is
responsive to plasma therapy (Bell, Chulay & Feinberg, 1997).
TTP is reported as a relatively rare complication in HIV in the United States in patients taking
Highly Active Anti-Retroviral Therapy (HAART), but is seen frequently in the developing world
where these drugs are not available (Sloand, 2005). Tamkus and co-workers used a dyad of
diagnostic criteria (microangiopathic haemolytic anaemia with fragments on the peripheral
smear and thrombocytopenia) to enroll 17 consecutive patients with HIV and TMA (1 HUS, 2
TTP/HUS and 14 TTP). The latter study reported these patients with TMA and HIV, to have
advanced HIV infection, as assessed by lower CD4 counts (median=28cells/ mm3) and higher
HIV-1 RNA levels (Tamkus, et al., 2006).
It has long been proposed that HIV infection predisposes to TTP and other TMA (Boccia, et
al., 1984; Jokela, Flynn & Henry, 1987). There has been a marked increase in cases reported
per year since the early 1990’s correlating with the AIDS pandemic (Torok, Holman & Chorba,
1995) and several early case series of reported AIDS cases support this (Hymes & Karpatkin,
1997; Leaf, et al., 1988; Ucar, et al., 1994). Leaf and co-workers documented 4 of 14 patients
(between 1985-1987) with TTP to be HIV positive (Leaf, et al., 1988). Ucar and co-workers,
noted 7 of 50 patients (from 1979-1990) with TTP to be HIV positive (Ucar, et al., 1994).
Subsequently a series by Hymes and Karpatkin documented the percentage of patients with
TTP and HIV (between 1990 to 1996) to be over 50% (Hymes & Karpatkin, 1997).
Although some acquired TMA appear to be either idiopathic in nature or secondary to direct
effects of HIV infection, there are some reports of co-existing AIDS-defining illnesses in these
patients (such as Kaposi sarcoma, cytomegalovirus, cryptococcal meningitis, Pneumocystis
carinii pneumonia) (Avery, Denuzio & Craig, 1998; Chu, et al., 1995; Leaf, et al., 1988;
Thompson, et al., 1992). Medications such as fluconazole, acyclovir and valacyclovir which
are used in the management of HIV positive patients have been associated as causal of TMA
syndromes (Bell, Chulay & Feinberg, 1997).
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The frequency of TMA appears to be even greater in those with more advanced HIV infection
and lower CD4 counts (Peraldi, et al., 1995; Ripamonti, et al., 1996; Tamkus, et al., 2006).
A prospective study of 350 HIV positive patients, revealed an incidence of TMA of 7%,
median CD4 counts were 36cells/mm3, median HIV-1 RNA levels were 94,000 copies/ml and
72% of patients presented with AIDS-defining illness (Moore, 1999).
Tamkus and co-workers suggest considering TMA as an AIDS-defining illness in order to
facilitate early recognition and effective treatment so as to improve the survival of this life-
threatening but treatable condition (Tamkus, et al., 2006). In 1984, an association was first
documented between HUS and HIV (Boccia, et al., 1984). HUS is a thrombotic
microangiopathy affecting glomeruli primarily, however the presenting features of HUS and
TTP may be difficult to distinguish (Tamkus, et al., 2006).
Early diagnosis of TTP is imperative for the immediate institution of life-saving plasma
exchange/ plasma infusion, however the diagnosis of TTP is complicated in the setting of HIV
where numerous other causes of thrombocytopenia may be present. As previously
mentioned, other causes for thrombocytopenia to consider in HIV include: defective
megakaryopoiesis with direct infection of megakaryocytes, sepsis, infections, antibody-
mediated platelet destruction, drugs, lymphoma and haemophagocytosis (Sloand, 2005;
Tamkus, et al., 2006).
A high index of suspicion is required for TTP in the setting of HIV in particular, where
numerous other causes for the cytopenias may be present. In addition several AIDS-related
infections and neoplasms have been shown to be associated with TMA, therefore the cause
for the TMA may be difficult to distinguish in HIV positive patients (Tamkus, et al., 2006).
In the presence of anaemia and thrombocytopenia, microangiopathic haemolysis
(DIC/TTP/HUS) must be excluded, which is detected by the presence of significant red cell
fragmentation on the peripheral smear with other features of haemolysis (such as a high LDH
level, raised Reticulocyte Production Index, unconjugated hyperbilirubinaemia, reduced
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Haptoglobin level). As the cytopenias in HIV positive patients are often multifactorial in nature,
assessment of VWFCP levels would be of value, not only as a baseline in HIV-infected
individuals without TTP, but also in HIV positive patients with TTP. VWFCP inhibitor titres
may help predict patients with a high possibility of relapse of TTP and these patients may
benefit from more aggressive therapy and antiretroviral therapy (Tamkus, et al., 2006).
The effect that HAART will have on the incidence of TMA in the setting of HIV positive
patients is not yet evident, but will probably be of significance (Blazes & Decker, 2004).
Gervasoni and co-workers prospectively assessed the incidence of TMA syndrome in 347
patients with AIDS during the period 1997 to 2000, during the HAART era, and as no cases of
TMA syndrome were observed during this time, they consider that antiretroviral therapy
significantly reduced the risk of TMA syndrome development (Gervasoni, et al., 2002). Becker
and co-workers revealed that TMA, in a cohort after introduction of HAART, was rare and was
associated with HIV infection that was advanced (Becker, et al., 2004).
Miller and co-workers documented relapse of TTP in two patients who discontinued HAART
against medical advice, possibly suggesting a causal role for HIV in this setting (Miller, et al.,
2005). Any other possible underlying conditions that may have precipitated TMA should also
be treated (Blazes & Decker, 2004). Complete deficiency of VWFCP and the presence of a
concentration-dependent IgG inhibitor was reported in one patient with HIV-associated TTP
(Sahud, et al., 2002).
1.12 Diagnostic utility of ADAMTS13 activity and inhibitor assays
Severe deficiency of ADAMTS13 is considered the primary cause of congenital and acquired
TTP (Levy, et al., 2001; Tsai & Lian, 1998; Moake, 2002; Furlan, et al., 1998). ADAMTS13
activity is reported as 50-178% in normal plasma (Veyradier, et al., 2001). Severe deficiency
of VWFCP activity (less than 5%) is a key finding confirming the diagnosis of TTP, whereas
mild to moderate deficiency is found in various other conditions (Studt, et al., 2003). A
universal cut-off value of ADAMTS13 activity for the diagnosis of TTP or ADAMTS13
deficiency is still to be established (Kokame, et al., 2005).
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There have been debates in the literature on the specificity of reduced ADAMTS13 levels for
the diagnosis of TTP (Mannucci, 2003). Tsai, takes the strongest standpoint that profound
ADAMTS13 deficiency (less than or equal to 0.1 UmL -1) is specific for TTP (Tsai, 2003).
Tsai, explains that other studies may report different findings due to variation in the methods
of ADAMTS13 activity measurement and in some studies the definition of TTP and HUS is
determined by referring physicians whose criteria of case definition are not specified (Tsai,
2003).
Current assays result in different ranges of values among normal individuals and reported
results are not comparable due to different assay methods and case definition (Tsai, 2003).
On the other hand, Remuzzi, highlights that a substantial proportion of adult cases with TTP
in two different series have normal ADAMTS13 levels (Remuzzi, 2003), ranging from 30%
(Veyradier, et al., 2001) to 38% (Raife, et al., 2002). Remuzzi, also discusses that
undetectable levels of ADAMTS13 were documented in two adult patients with familial HUS
(Remuzzi, et al., 2002), in 4 adults with secondary forms of HUS (Veyradier, et al., 2001), in
one adult with post-diarrhoeal HUS (Veyradier, et al., 2001).
However, TTP and HUS are often regarded as variants of one syndrome denoted as
TTP/HUS (Furlan & Lämmle, 2001). Furlan and Lämmle, demonstrated that most if not all
patients with classic TTP have severe ADAMTS13 deficiency, but not all individuals with
congenital ADAMTS13 deficiency develop acute TTP (Furlan & Lämmle, 2001).
An acute event of TTP in a patient with congenital ADAMTS13 deficiency tends to be followed
by a chronic and relapsing form of TTP (Furlan & Lämmle, 2001). The prevalence of
congenital ADAMTS13 deficiency may be under-diagnosed as some severe ADAMTS13
deficiencies remain undetected in asymptomatic subjects. It is also possible that individuals
with acquired ADAMTS13 deficiency may also escape detection as the autoantibodies
against ADAMTS13 may disappear before the development of an acute episode of TTP
(Furlan & Lämmle, 2001). As reported by Furlan and co-workers, a patient with acquired TTP
had his first relapse 3 months subsequent to the antibody-mediated decrease of the protease,
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thereby suggesting that a specific pathophysiological condition was required to trigger
commencement of the acute episode (Furlan, et al., 1998).
Furlan and co-workers, have also observed that in patients with acquired TTP, remission may
occur prior to the complete normalisation of ADAMTS13 and disappearance of the inhibitor
(Furlan, et al., 1998). These considerations of acute TTP in severely ADAMTS13 deficient
individuals may be paralleled with patients with genetic predispositions to venous
thrombophilia (such as Factor V Leiden or deficiencies of Protein C and Protein S) or
acquired risk factors (such as oral contraceptives, antiphospholipid antibodies, pregnancy,
trauma, malignancy, previous thrombotic episodes), where a single risk factor may not be
sufficient to cause thrombosis (Furlan & Lämmle, 2001). However, if several risk factors
accumulate then the chance of a thrombotic event increases and the recurrence rate is high
thereafter (Furlan & Lämmle, 2001). It is not certain why some individuals with severe
congenital ADAMTS13 deficiency experience episodes of acute TTP in childhood, whilst
others remain asymptomatic for decades (Furlan & Lämmle, 2001).
ADAMTS13 deficiency is evidently a very strong risk factor for TTP, however the occurrence
of an acute microangiopathy requires a trigger, such as alcohol abuse, pregnancy or bacterial
or viral infection (Furlan & Lämmle, 2001). In general it is considered that this trigger results in
activation or death of the microvascular endothelial cells, thereby resulting in the release of
ULVWF multimers from the storage organelles (Furlan & Lämmle, 2001).
1.12.1 VWFCP levels may be altered in settings other than TTP
Mild to moderate reduction in ADAMTS13 levels is reported in other conditions such as
inflammation, coronary artery disease (Yoo, et al., 2003), disseminated intravascular
coagulopathy (Loof, van Vliet & Kappers-Klunne, 2001), pregnancy, liver disease (Mannucci,
et al., 2001), sepsis, heparin-induced thrombocytopenia (Bianchi, et al., 2002) and in patients
with metastasizing and malignant tumours (Böhm, et al., 2003b; Oleksowicz, Bhagwati &
DeLeon-Fernandez, 1999).
46
Mannucci et al measured VWFCP levels in 177 control subjects of different ages, in 26 full-
term newborns and in 69 pregnant women (Mannucci, et al., 2001). In addition, VWFCP
levels were assessed in 42 patients with decompensated liver cirrhosis, 63 patients with
chronic uraemia, 15 patients with acute inflammatory states and 24 patients in the post-
operative setting (Mannucci, et al., 2001).
VWFCP levels were found to be low in newborns, however levels normalised at 6 months of
age and VWFCP levels were lower in the last two trimesters of pregnancy compared to the
first trimester (Mannucci, et al., 2001). VWFCP levels were also found to be low in patients
with cirrhosis, uraemia, acute inflammation and levels fell in the post-operative period
(Mannucci, et al., 2001). Mannucci and co-workers concluded that low VWFCP levels are not
specific to TTP as low levels are also found in several physiological and pathological
conditions (Mannucci, et al., 2001).
Moore and colleagues also demonstrate reduced ADAMTS13 activity in 6 of 20 patients with
Idiopathic Thombocytopenic Purpura (ITP), 5 of 10 patients with Systemic Lupus
Erythematosis (SLE), 6 of 10 patients with DIC, 1 of 5 patients with leukaemia, 3 of 25
hospitalised patients and 2 of 20 healthy controls (Moore, et al., 2001).
Lämmle and co-workers discuss that although some studies suggested that VWFCP
deficiency was not specific for TTP, VWFCP was either not rigorously quantitated or was only
moderately decreased (Lämmle, Kremer Hovinga & Alberio, 2005). In a study by Bianchi and
co-workers, VWFCP levels were assessed in 68 patients with thrombocytopenia from various
causes except TTP or HUS. Twelve patients were found to have levels lower than 30%. None
had levels <10% which is in clear contrast to patients with acute TTP (Bianchi, et al., 2002). A
severely deficient VWFCP activity (<5% of normal) is suggested as specific for TTP (Lämmle,
Kremer Hovinga & Alberio, 2005).
Subsequent cohort studies on patients diagnosed with acute idiopathic TTP demonstrated
marked variability in ADAMTS13 activity (Furlan, et al., 1998; Tsai & Lian, 1998; Vesely, et
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al., 2003; Peyvandi, et al., 2004a; Veyradier, et al., 2001; Mori, et al., 2002; Kremer Hovinga,
et al., 2004; Matsumoto, et al., 2004; Zheng, et al., 2004). Severe protease deficiency was
defined as <5% of normal in all studies, except in the study by Peyvandi and co-workers,
where it was defined as <10% (Lämmle, Kremer Hovinga & Alberio, 2005).
Lämmle and co-workers discuss that not all patients clinically diagnosed with idiopathic TTP
may have severe ADAMTS13 deficiency as measured with static protease activity assays
(Lämmle, Kremer Hovinga & Alberio, 2005). Lian attributes the variation in reports of
ADAMTS13 deficiency in idiopathic TTP to the fact that ADAMTS13 deficiency may not be the
cause of platelet thrombi in approximately 40% of patients and that other contributing
pathogenic factors may be involved in these cases of idiopathic TTP (Lian, 2005). Kokame
and co-workers, demonstrated an association of ADAMTS13 activity with gender and age
suggesting that ADAMTS13 activity of women should be significantly higher than that of men
and that plasma ADAMTS13 activity should decrease at least after the early 40s (Kokame, et
al., 2005).
Galbusera and co-workers, reported that nearly all patients during the acute phase of
thrombotic microangiopathy had increased proteolytic fragments of VWF (176kDa and
140kDa), independently of normal or deficient ADAMTS13 activity (Galbusera, et al., 1999a).
ADAMTS13 cleavage of VWF is known to generate 176kDa and 140 kDa fragments, and
Remuzzi, emphasizes that other proteins may be involved in the cleavage of VWF in
thrombotic microangiopathy patients. Although ADAMTS13 inhibits VWF function in vitro, it
may also function to prevent microangiopathy by cleaving other unknown proteins involved in
the coagulation system or endothelial integrity regulation (Remuzzi, 2003).
ADAMTS13 activity as low as 5-10% may be sufficient for the prevention of microvascular
platelet thrombi and parents of TTP patients with ADAMTS13 activity as low as 6-20% are
generally asymptomatic (Sasahara, et al., 2001).The ability of assays to screen for
ADAMTS13 deficiency and to distinguish between hereditary and acquired deficiency is
relevant due to differences in patients’ therapeutic management. However further work is
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required to improve functional methods as well as the standardisation of ADAMTS13 activity
(Wyrick-Glatzel, 2004).
The ULVWF multimers appear to undergo proteolytic processing to smaller multimers directly
on the surface of the endothelial cell (Wyrick-Glatzel, 2004). Abnormal processing of the
ULVWF multimers and microthrombi formation may occur due to either autoantibody
formation or a structural defect of the ADAMTS13 molecule that prevents the binding of
ADAMTS13 to the endothelial cell receptor (Wyrick-Glatzel, 2004).
Current assays available do not detect defective binding of ADAMTS13. Further development
of endothelial based assays of ADAMTS13 activity may better define cases of TTP without
severe deficiency of ADAMTS13 that results from impaired binding (Wyrick-Glatzel, 2004).
The clinical utility of an ADAMTS13 assay still remains a matter of considerable debate
(Remuzzi, 2003; Tsai, 2003; Mannucci, 2003) which may in part be related to interassay
variability (Shelat, Ai & Long Zheng, 2005). Laboratory assays for ADAMTS13 activity must
reliably assess severe deficiency and inhibitory antibodies (Studt, et al., 2003).
Although the specificity of low ADAMTS13 levels for the diagnosis of TTP, HUS or other
thrombotic microangiopathies has been debated in the literature (Tsai, 2003; Remuzzi, 2003),
measurement of ADAMTS13 may be of value in patient management (Tripodi, et al., 2004).
Severe deficiency of ADAMTS13 activity of less than 5% in a patient with clinical symptoms of
an acute thrombocytopenia and evidence of a microangiopathic haemolytic anaemia (in
particular red cell fragments on peripheral smear), appropriately defines the diagnosis of TTP.
However severely deficient ADAMTS13 activity may not always produce the clinical entity of
TTP (Wyrick-Glatzel, 2004). Therefore correlation of ADAMTS13 activity with other laboratory
and clinical findings is essential.
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1.13 Overview of VWFCP assays
ADAMTS13 assays can be divided into static versus flow based and direct versus indirect
(Shelat, Ai & Long Zheng, 2005). Refer to Table 1 for a summary of VWFCP assays.
Table 1. Summary of Direct versus Indirect assays available for the measurement of VWFCP
levels.
Direct Assays Indirect Assays
SDS-PAGE & Western Blotting Collagen-Binding Assay
Fluorescent Resonance Energy
Transfer (FRETS) assay
Ristocetin-Induced Aggregation
Flow-based Assays
New ELISA using recombinant
VWF-A2 domain as substrate
Central to each assay is two distinct steps. The first step involves proteolysis of a substrate by
plasma containing ADAMTS13. Substrates include exogenous, endogenous, purified
fragments or recombinant VWF. The substrate usually requires unfolding with the use of
either urea or guanidine and ADAMTS13 is usually activated with the use of divalent cations.
Various test plasma concentrations are utilised (Wyrick-Glatzel, 2004).
The second step involves the quantitation of the remaining substrate or the residual VWF
after proteolytic cleavage. Quantitation of substrate may be performed by, electrophoresis
(detection of fragments or the generation of smaller multimers), immunological methods
(ELISA, Immunoradiometric assays/ IRMA which use monoclonal antibodies to VWF), or the
measurement of functional activity (Ristocetin cofactor activity of VWF or the decrease of
collagen binding) (Wyrick-Glatzel, 2004).
Assays for detecting ADAMTS13 activity in TTP have been in use from 1998. The method by
Tsai and co-workers, is the only method that measures the generation of VWF degradation
products by ADAMTS13 proteolysis (Tsai & Lian, 1998; Wyrick-Glatzel, 2004). Direct assays
detect the cleavage products of a particular substrate such as macromolecular VWF, the A2
domain of VWF or the small synthetic 73-amino-acid peptide FRETS-VWF73 (fluorescence
resonance energy transfer) (Shelat, Ai & Long Zheng, 2005; Kokame, et al., 2005). The
cleavage products of the substrate have been detected by Agarose or polyacrylamide gel
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electrophoresis (PAGE), Western blotting and the FRETS techniques (Shelat, Ai & Long
Zheng, 2005).
Indirect assays depend on the measurement of residual substrate or on disappearance of the
substrates. Examples of indirect assays include the Collagen–binding assay (Gerritsen, et al.,
1999) and modifications of this assay (Rick, et al., 2002; Zheng, et al., 2004; Mannucci, et al.,
2001), Ristocetin-induced aggregation, flow-based assays and Enzyme-linked
immunosorbent assay (Shelat, Ai & Long Zheng, 2005).
Tsai and co-workers, used a direct method which measures the product of ADAMTS13
enzymatic activity by means of SDS-PAGE which detects the cleavage products of purified
VWF as dimers of 176-kd and 140-kd fragments with a normal range of VWFCP activity of
68%-126% in the control group (Tsai & Lian, 1998).
The collagen binding assay by Gerritsen and co-workers (normal range of 28%-119%), the
two-site immunoradiometric assay by Obert and co-workers (normal range of 50%-150%), the
method of quantitative immunoblotting of cleaved or degraded VWF multimers by Furlan and
co-workers (normal range of >50%) and the method using ristocetin cofactor activity by Böhm
and co-workers (normal range of 52%-134%), are all indirect methods for the measurement of
ADAMTS13 activity (Böhm, Vigh & Scharrer, 2002; Gerritsen, et al., 1999; Obert, et al., 1999;
Furlan, et al., 1997).
However all the above-mentioned indirect methods and the direct method by Tsai and co-
workers, are based upon static and non-physiological settings (with the use of denaturing
conditions with either urea or guanidine, barium ions and long incubation periods), instead of
more physiological conditions on the endothelial cell surface under fluid shear forces (Amar,
et al., 2002; Dong, et al., 2002; Shenkman, et al., 2002; Shenkman, et al., 2003). Inhibitory
antibodies to ADAMTS13 may be detected by all of the functional assays for ADAMTS13 with
a wide range of sensitivities (Shelat, Ai & Long Zheng, 2005). ADAMTS13 autoantibodies
may be classified into either inhibitory or noninhibitory antibodies, which is based on whether
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the antibodies block proteolytic cleavage of VWF in an in vitro assay (Shelat, Ai & Long
Zheng, 2005).
Proteolytic activity of ADAMTS13 may be blocked in vitro if the autoantibodies target
ADAMTS13 proximally, whereas in vitro activity of ADAMTS13 may not be blocked if the
autoantibodies target the middle and distal carboxyl terminus of ADAMTS13 (Soejima, et al.,
2003). Inhibitory antibodies thus far react with the Cys-rich and spacer domains and have
some specificity to other parts of the ADAMTS13 molecule including the catalytic domain
(Klaus, et al., 2004). This supports the essential role of the Cys-rich and spacer domains in
substrate recognition (Zheng, et al., 2003a; Soejima, et al., 2003; Ai, et al., 2005).
1.13.1 Inhibitor Assays
As per an unpublished observation by Shelat and co-workers, the FRETS-VWF73 assay
appears the most sensitive out of three evaluated assays (collagen-binding assay, GST-
VWF73 and FRETS-VWF73) of detecting inhibitory autoantibodies (Shelat, Ai & Long Zheng,
2005).
Both inhibitory and non-inhibitory autoantibodies may be detected by an ELISA assay along
with Western blotting using recombinant ADAMTS13 as an antigen (Rieger, et al., 2005).
Rieger and co-workers report IgG antibodies in 97% of untreated patients with acute acquired
TTP whose ADAMTS13 plasma levels are below 10% and a corresponding prevalence of IgM
antibodies of 11% (Rieger, et al., 2005). The presence of ADAMTS13 autoantibodies is
considered fairly specific for making a diagnosis of acquired TTP (Tsai & Lian, 1998; Tsai,
2003). A high inhibitory autoantibody titre correlates with a greater number of relapses
(Shelat, Ai & Long Zheng, 2005).
Adjunctive immune therapies including Rituximab TM (anti-CD20 chimeric monoclonal
antibody) or cyclophosphamide are considerations in patients who chronically relapse or who
do not respond adequately to plasmapheresis (Zheng, et al., 2003b; Zheng, et al., 2004;
Fakhouri, et al., 2004; Fakhouri, et al., 2005). A robust ADAMTS13 inhibitor assay is essential
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for both understanding the mechanism of TTP and for adjusting therapeutic modalities
(Shelat, Ai & Long Zheng, 2005).
1.13.2 Direct Assays
 SDS-PAGE and Western blotting
This assay was initially developed by Tsai and co-workers and is based on detection of the
170kDa and 140kDa VWF fragments on denatured, but unreduced SDS-PAGE and Western
blotting (Tsai, 1996; Tsai & Lian, 1998; Tsai, et al., 1997).
This assay differs from the SDS-Agarose method developed by Furlan and co-workers by: no
requirement for barium chloride activation; easier to work with gels from SDS-PAGE than
agarose gel electrophoresis; relatively short incubation period of 1-3 hours; the cleavage
product is visualised directly thereby eliminating the possibility of non-specific degradation of
the multimers (Shelat, Ai & Long Zheng, 2005; Tsai & Lian, 1998; Furlan, Robles & Lämmle,
1996; Furlan, et al., 1997; Furlan, et al., 1998).
After the reaction products have been separated by SDS-Agarose or SDS-PAGE gel
electrophoresis, this is followed by Western blotting analysis with anti-VWF antibodies
(Furlan, Robles & Lämmle, 1996; Tsai, 1996).
This SDS-PAGE assay detected less than 5% of normal ADAMTS13 activity (severe
deficiency) in all 37 patients with idiopathic TTP and inhibitory activity against ADAMTS13
was detected in 67% (Tsai & Lian, 1998). This assay is sensitive enough to distinguish
between patients with congenital TTP, asymptomatic carriers and healthy individuals and
precise mapping of the defective ADAMTS13 gene can be performed (Levy, et al., 2001).
Although these assays have significantly increased the understanding of ADAMTS13 and the
pathogenesis of TTP, due to technical complications these assays are not widely used at the
clinical level (Kokame, et al., 2005).
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 Fluorescent Resonance Energy Transfer (FRETS) assay
Kokame and co-workers, developed a synthetic 73-amino-acid fluorogenic peptide, FRETS-
VWF73, containing the 73 amino acids from D1596 to R1668 of VWF. The Q1599 residue at
the P7 position was converted to a 2,3-diaminopropionic residue (A2pr) which was modified
with a 2-(N-methylaminobenzoyl group (Nma) and the N1610 residue of the P5’ position was
converted to A2pr which was modified with a 2,4-dinitrophenyl group (Dnp). At 340nm, the
Nma group is excited and fluorescence resonance energy is transferred to Dnp, the
neighbouring quencher. However if the bond between Y1605 and M1606 is cleaved, the
fluorescence energy transfer quenching does not occur and this allows the emission of
fluorescence from Nma at 440nm (Kokame, et al., 2005). Refer to Figure 4 for a graphical
depiction of the structure of the FRETS substrate (as per Kokame, et al., 2005).
Figure 4. Schematic representation of structure of fluorescence resonance energy transfer
(FRETS)-Von Willebrand factor (VWF)-73 substrate. Amino acid residues Q1599 and N1610 (
which are within the 73 amino acid peptide corresponding to the region D1595-R1668of VWF)
are replaced by A2pr (Nma) and A2pr (Dnp) respectively. The arrow indicates the cleavage
site of ADAMTS13. Diagram from: Kokame, K., Nobe, Y., Kokubo, Y., et al. 2005. FRETS-
VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol, vol.129, pp. 94.
FRETS-VWF73 is a monomeric molecule which has a single cleavage site as opposed to the
previously established substrate, purified plasma VWF which comprised of non-uniform
multimers with multiple cleavage sites (Kokame, et al., 2005). Denaturants are not required
for the reaction, thereby making this assay closer to physiological conditions. This assay
follows a simple procedure and special reagents or equipment is not required other than a
fluorescence spectrophotometer. Proposed uses for this assay include potential clinical
diagnostics and selection of plasma with high titre ADAMTS13 activity for treatment purposes
(Kokame, et al., 2005).
54
A universally applicable cut-off value for ADAMTS13 activity for the diagnosis of TTP or
ADAMTS13 deficiency is still to be established and the definition of standard plasma is of
primary importance (Kokame, et al., 2005). Purified or recombinant ADAMTS13 availability
may assist in the standardisation of ADAMTS13 assays and the age and gender distribution
of ADAMTS13 will need to be established in the general population (Kokame, et al., 2005).
The FRETS-VWF73 assay is a high-throughput assay that would facilitate performing large
population-based studies (Kokame, et al., 2005).
1.13.3 Indirect Assays
 Collagen-Binding Assay
Collagen-binding assays are based on the preferential binding of large VWF multimers to type
III human collagen (Gerritsen, et al., 1999; Mannucci, et al., 2001; Rick, et al., 2002; Zheng, et
al., 2003a). These assays have some variations in the initial method, with some employing
the use of incubation with purified VWF (Gerritsen, et al., 1999) but all culminate in
quantitation of the residual amount of VWF binding to collagen by means of peroxidase
conjugated anti-VWF antibody on an ELISA plate (Gerritsen, et al., 1999; Rick, et al., 2002;
Zheng, et al., 2003a; Zheng, et al., 2004).
This assay can accommodate many samples simultaneously and is considered quite robust in
the detection of severe deficiency of ADAMTS13 (16 of 20 patients) and high titre inhibitors (7
of 16 patients) in idiopathic TTP (Zheng, et al., 2004). This assay correlates well with other
indirect assays (Tripodi, et al., 2004). We have set up the rapid collagen binding assay as per
Rick and co-workers.
A modification of this assay is used to assess for the presence of an inhibitor to ADAMTS13,
by incubation of patient sample with pooled normal plasma (Rick, et al., 2002; Zheng, et al.,
2004). The presence of high-titre inhibitors in TTP patients is associated with a delayed
response to plasmapheresis and refractory disease (Zheng, et al., 2004; Vesely, et al., 2003;
Veyradier, et al., 2001). Assessment of ADAMTS13 inhibitor titres may be useful for the
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identification of patients with a high possibility of relapse as this group of TTP patients may
benefit from intensive immunotherapy in addition to plasmapheresis (Zheng, et al., 2004).
This assay may be used for diagnostic purposes, therapeutic monitoring and for predicting
outcome (Shelat, Ai & Long Zheng, 2005).
The collagen binding assay (without the dialysis step) is also of value in the diagnosis of Type
2A and Type 2B Von Willebrand’s Disease, where high molecular weight multimers of VWF
are either absent or deficient (Favaloro, 2000). An ELISA test for the binding of VWF to
collagen was first described in 1986 by Brown & Bosak and has subsequently been modified
(Brown & Bosak, 1986; Favaloro, 2000).With respect to Von Willebrand disease assessment,
the collagen source is of importance (Favaloro, 2000).
A collagen binding assay can be used in the diagnosis and subtype discrimination of Von
Willebrand disease depending on two variables: the generation of an adequate VWF-dose-
dependent calibration curve and the ability to detect only the most functional VWF forms (the
high and intermediate weight molecular weight multimers of VWF are preferentially detected)
(Favaloro, 2000).
Not all collagen preparations provide an effective VWF-dose-dependent calibration curve and
the ability of the collagen-based assay to preferentially detect high and intermediate
molecular weight VWF multimers also depends on the type of collagen used and there may
be batch/ lot dependency (Favaloro, 2000). Therefore optimal assay conditions need to be
established with respect to collagen concentration, buffer choice and collagen coating
incubation time (Favaloro, 2000).
Favaloro makes recommendations for ELISA collagen-binding assays with respect to Von
Willebrand disease assessment including the use of a Type I/III collagen mixture product
(used at 10-50μg/ml) or a pure Type III collagen (used at 1-5μg/ml) (Favaloro, 2000). Bovine
and equine collagen sources have shown comparable results (Favaloro, 2000; Favaloro,
2002).
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For the purposes of Von Willebrand disease detection, the use of purified Type I collagen is
not recommended, due to low efficacy, reproducibility or both (Favaloro, 2000; Favaloro,
2002). However, for the purposes of this study, Vitrogen TM Collagen was used which is a
purified bovine Type I Collagen, as used by Rick et al, for the purposes of VWFCP activity (as
measured by % residual collagen binding activity). This differs from VWF antigen detection
where generation of an adequate VWF-dose-dependent calibration curve is required. It
should be noted that data on different collagen sources for the purpose of the residual
collagen binding assay for VWFCP activity is not available.
 Ristocetin-Induced Agglutination
This assay utilises purified VWF which is digested in buffer and the residual VWF is
determined with the use of ristocetin cofactor activity in a platelet aggregometer (Shelat, Ai &
Long Zheng, 2005). The method has been shown to be reproducible and severe ADAMTS13
deficiency in patients with acute TTP is detected (Böhm, Vigh & Scharrer, 2002). However
this assay has not been widely used as only a limited number of samples can be analysed on
the aggregometer at a time (Shelat, Ai & Long Zheng, 2005).
 Flow-based assays
Shenkman and colleagues, used a cone and platelet analyser to determine the ability of TTP
plasma versus normal plasma, to increase platelet deposition on a polystyrene surface under
flow conditions (Shenkman, et al., 2003). The assay is sensitive and specific for the
assessment of ADAMTS13 deficiency and inhibitors. The deposition of normal platelets was
increased following addition of plasma in all 15 patients with acute TTP but only in three of 14
patients in remission (Shenkman, et al., 2003).
Dong and colleagues, described that when released from cultured endothelial cells, ULVWF
multimers form extremely long, platelet-decorated string-like structures on the surface of
endothelial cells under conditions of fluid shear stress (Dong, et al., 2002). When perfused
with plasma from patients with TTP, the string-like structures are not cleaved, whereas in the
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presence of normal plasma, the string-like structures disappear rapidly due to the cleavage of
ULVWF multimers by ADAMTS13 in the perfused plasma (Dong, et al., 2002).
This suggests that ADAMTS13 binds to the endothelial cell and locally cleaves the
exceptionally adhesive ULVWF multimers (Dong, et al., 2002). An endothelial cell dependant
assay may shorten the method and reflect the function of ADAMTS13 in a more physiological
manner (Amar, et al., 2002).
Moake hypothesised that there may be defective anchoring of ADAMTS13 to the endothelial
cell surface (Moake, 2002), this may be related to possible structural defects of the
ADAMTS13 molecule (Studt, et al., 2003) or to anti-CD36 antibodies (Tandon, Rock &
Jamieson, 1994). In such cases severe ADAMTS13 dysfunction may not be detected by the
other methods discussed but may only be detected by an endothelial-based assay. This could
also explain the presence of clinically distinct TTP patients with normal ADAMTS13 activity
(Mori, et al., 2002; Vesely, et al., 2003; Studt, et al., 2003; Wyrick-Glatzel, 2004).
 New Enzyme-Linked Immunosorbent Assay using recombinant VWF-A2 domain
as a substrate
Whitelock et al, succeeded in culturing bacteria which expressed a recombinant VWF-A2
peptide (amino acid 718—905). This peptide contains both a 6xHis tag at the N-terminal end
and a Tag-100 epitope at the C-terminal end and is used as a substrate for this assay
(Whitelock, et al., 2004; Zhou & Tsai, 2004). The VWF substrate is immobilised on a
microtitre plate. A Ni2+-coated microtitre plate is utilised as the Ni2+ captures the VWF-A2
peptide by its 6xHis tag and cleavage of the A2 peptide is ascertained by the removal of the
C-terminus of the peptide that contains the Tag-100 (Whitelock, et al., 2004).
Samples are incubated with the substrate, the cleavage activity is defined by low detection of
the A2 peptide containing the Tag-100 epitope by means of an antiTag-100 monoclonal
antibody thereby detecting the residual substrate present (Whitelock, et al., 2004).
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The proteolytic activity of ADAMTS13 is inversely proportional to the amount of residual VWF
substrate present. The VWF A2 domain ELISA detected residual ADAMTS13 activity in TTP
patients of 2.4 + /- 0.7% compared with 40 + /- 4.2% in normal plasma and these results were
validated with the use of a traditional long incubation immunoblotting method (Whitelock, et
al., 2004). TTP patients can be distinguished from carriers of ADAMTS13 gene mutation and
normal healthy individuals (Zhou & Tsai, 2004).
This assay is reproducible, cost-effective, can be performed in less than 5 hours and
measures ADAMTS13 activity under non-denaturing and physiological conditions (Whitelock,
et al., 2004). As this is an ELISA-based method, lengthy electrophoresis is avoided
(Whitelock, et al., 2004). Another advantage of this assay is the use of purified recombinant
VWF-A2 peptide as a substrate which allows standardisation of the substrate, thereby
avoiding variability among various batches of VWF preparation including antigen levels and
multimer distribution. In addition, the cleavage of recombinant VWF-A2 peptide occurs
without the addition of metal ions and under physiological buffer saline with a pH of 7.4.
Other assays require addition of specialised buffers containing Ba2+ or Ca2+ ions and a higher
pH to promote the enzyme to cleave full-length VWF. Urea is not required to unfold the
substrate due to the constitutively exposed cleavage site of the A2 peptide (Whitelock, et al.,
2004).
Significantly shorter incubation time and less plasma (activity at 1:50 dilution detected) is
required for cleavage of the VWF-A2 domain. This is related to the readily accessible open
conformation of VWF-A2. The A2 domain appears to be masked in native VWF multimers by
other adjacent structures such as the A1 and A3 domains (Whitelock, et al., 2004).
This may explain why ADAMTS13 cleaves the ULVWF formed under fluid shear stress, one
thousand fold faster than under static conditions (Whitelock, et al., 2004; Dong, et al., 2002).
As the ULVWF strings tethered with platelets are subjected to noteworthy amounts of wall
shear stress which may stretch VWF to the extent of exposing the A2 domain (Whitelock, et
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al., 2004). This concurs with previous studies by Tsai et al., which demonstrated that fluid
shear stress accelerates VWF cleavage by ADAMTS13 (Tsai, Sussman & Nagel, 1994).
Rapid diagnosis of TTP and other conditions that may result in ADAMTS13 deficiency may be
enhanced by the fast turnaround time of the ELISA method (Whitelock, et al., 2004).
1.14 Studies comparing different assays
Studt et al, published a study based upon the comparison of the results obtained from five
different laboratories on the same samples: one used the immunoblotting assay, two utilised
the residual collagen binding activity, one used the residual ristocetin cofactor activity and one
used the immunoradiometric assay (Studt, et al., 2003).
The purpose of this study was to assess whether or not there was concordance of the 4
different techniques used in 5 different laboratories to assess 30 plasma samples from
patients with hereditary and acquired TTP and other clinical conditions associated with altered
ADAMTS13 activity with levels ranging from <3% to >100% (Studt, et al., 2003). This study
also evaluated whether or not plasma containing ADAMTS13 inhibitory antibodies could be
distinguished from plasma without antibodies (Studt, et al., 2003).
With few exceptions, the methods used by all laboratories identified plasma with severe
ADAMTS-13 deficiency (<5%) and plasma with strong inhibitor activity (Studt, et al., 2003).
There was less consistency of interassay and inter-laboratory results for plasma samples with
normal or moderately reduced ADAMTS13 activity (Studt, et al., 2003). However this study
demonstrated that these methods developed for ADAMTS13 detection showed good general
agreement between the assays concerning the identification of severe ADAMTS13 deficiency
and did not indicate a systematic deviation for any method. These assays are therefore
considered clinically useful and relevant as a screening test in suspected TTP patients (Studt,
et al., 2003).
The collagen binding assay is widely used due to its relative simplicity, however in this study
three samples were misclassified by two laboratories (one false negative and two falsely
60
positive) (Studt, et al., 2003). The false negative result was in a confirmed patient with
hereditary TTP, where one laboratory obtained a result of ADAMTS13 activity of 44% (all
other laboratories diagnosed a severe deficiency of ADAMTS13 with less than 5%
ADAMTS13 activity). One laboratory obtained two false positive results where a severe
ADAMTS13 deficiency was diagnosed in two patients, whereas all other laboratories found
only a mild to moderate decrease in ADAMTS13 activity (10-25% in the one patient and 15-
35% in the other patient) (Studt, et al., 2003).
The collagen binding assay appears to be subject to disturbance and is delicate and some
improvement in terms of accuracy is required, although no systematic error was identified
(Studt, et al., 2003). Substantial discrepancies may also occur with other methods (Mannucci,
2003).
The immunoblotting assay is reproducible in the lowest activity range, is very sensitive and
allows distinction between 3% and 0% activity and depending on the VWF substrate quality,
this assay may distinguish between 1% and 0% activity (Studt, et al., 2003). However the
disadvantage of the immunoblotting assay is the labour-intensive and time-consuming
method which limits the application of this method to use in a specialised laboratory setting
(Studt, et al., 2003).
The limitation of this study, is that precision and reproducibility were not specifically evaluated
which are important criteria for laboratory method validation (Mannucci, 2003). Thereafter
another multicentre study was co-ordinated to include a wider array of tests (Mannucci, 2003;
Tripodi, et al., 2004). Tripodi and co-workers, performed an international collaborative study of
eleven methods for ADAMTS13 measurement in different laboratories testing the same set of
coded plasmas (Tripodi, et al., 2004). Two plasmas, one from a patient with familial TTP and
one normal were mixed at the co-ordinating centre to obtain 6 plasmas with varying
concentration of ADAMTS13 activity ranging from 0%, 10%, 20%, 40%, 80% and 100%
(Tripodi, et al., 2004). Nine of the ten methods performed under static conditions were
quantitative and one was semi-quantitative (Tripodi, et al., 2004).
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Four laboratories used the collagen binding assay (as per Gerritsen, et al., 1999), one used
the semi-quantitative rapid collagen binding assay (as per Rick, et al., 2002), one used
residual ristocetin cofactor activity (as per Böhm Vigh & Scharrer, 2002), one used
quantitative immunoblotting of degraded substrate of VWF multimers (as per Furlan, et al.,
1998), one used immunoblotting of unreduced VWF multimers (as per Amar, et al., 2002),
one used an immunoradiometric assay (IRMA) with monoclonal antibodies to the N and C-
terminal subunits (as per Obert, et al., 1999), and one used SDS-PAGE and quantitative
immunoblotting of a recombinant VWF polypeptide which includes domains A1-A2-A3 of VWF
(as per Remuzzi, et al., 2002).
One method was not static and was carried out under flow conditions to assess the extent of
cleavage of endothelial cell derived ULVWF string-like structures with attached platelets
under fluid shear stress (as per Amar, et al., 2002). The latter method expressed results as
deficient, normal or borderline (Tripodi, et al., 2004).
Linearity of the expected versus the observed levels with the use of the squared correlation
coefficient (r2), ranged from 0.98 to 0.39. Reproducibility for repeated measurements
assessed with the coefficient of variation ranged from <10% to 83% (Tripodi, et al., 2004).
The majority of the methods were successful at discriminating between the different levels of
ADAMTS13 and this is an important characteristic as both reproducibility and accuracy are
taken into account (Tripodi, et al., 2004).
The discrimination between different ADAMTS13 levels was performed best by two of the
collagen binding assays, the ristocetin cofactor assay and the SDS-agarose electrophoresis
and immunoblotting of degraded VWF multimers. However these methods have little in
common in terms of assay design (Tripodi, et al., 2004).
Another important characteristic of methods measuring ADAMTS13 is the ability to detect
severe ADAMTS13 deficiency and the majority of the assays could detect ADAMTS13 levels
of 0% (Tripodi, et al., 2004).
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Some assays could distinguish between levels of 0% and 10% of ADAMTS13 namely one of
the collagen binding assays, the ristocetin cofactor activity assay and the assay using SDS
agarose electrophoresis and immunoblotting of degraded VWF multimers (Tripodi, et al.,
2004).
The overall best performance was noted for three methods: the ristocetin cofactor activity, the
collagen binding assay and the immunoblotting of degraded multimers of VWF substrate
(Tripodi, et al., 2004). The method performed under flow conditions identified the plasma
samples of 80% and 100% as normal in all 10 repeated measurements and the 0%, 10%,
20% and 40% activity was detected respectively as deficient in 7, 5, 1 and 3 of the 10
repeated measurements (Tripodi, at al., 2004). This method may be reliable in distinguishing
ADAMTS13 levels higher or lower than 20%. As the latter assay reported results as normal,
borderline or deficient based on the percentage of strings cleave after 2 minutes of perfusion,
reproducibility and linearity of this method could not be assessed (Tripodi, et al., 2004).
The best concordance between expected and achieved ADAMTS13 levels was found in two
methods. These include one of the laboratories using the collagen binding assay (by
Gerritsen, et al., 1999, using purified VWF, not semi-quantitative method) with r2=0.97, and
one of the laboratories using the ristocetin cofactor activity assay (by Böhm, Vigh & Scharrer,
2002, using purified VWF) with r2=0.98 (Tripodi, et al., 2004).
Reproducibility studies revealed that the most precise methods were the semi-quantitative
collagen binding assay (as per Rick, et al., 2002) and the ristocetin cofactor activity where the
average coefficient of variation was less than 10% (Tripodi, et al., 2004). Intermediate
precision was achieved by 2 collagen binding assay and the SDS agarose electrophoresis
and immunoblotting of VWF multimers (average coefficient of variation between 12-15%).
Two other collagen binding assays, the IRMA, the SDS-PAGE and quantitative
immunoblotting of recombinant VWF polypeptide and the SDS-agarose and immunoblotting
of ULVWF multimers yielded average coefficient of variation results from 30-83% (Tripodi, et
al., 2004).
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In terms of the overall ability of each method to discriminate between different ADAMTS13
levels, the ristocetin cofactor activity, two collagen binding assays and the SDS agarose
electrophoresis and immunoblotting of degraded VWF multimers revealed good discrimination
(Tripodi, et al., 2004). Intermediate discrimination between different ADAMTS13 levels was
noted with the semi-quantitative rapid collagen binding assay, two collagen binding assays
and the SDS-PAGE and quantitative immunoblotting of a recombinant VWF polypeptide. Low
discrimination was noted with the IRMA method and the SDS-agarose and immunoblotting of
unreduced VWF multimers (Tripodi, et al., 2004).
The ability of each method to distinguish between the 0% and 10% ADAMTS13 plasmas
could not be statistically determined as the results obtained by the majority of methods for the
0% plasma were below detection limits (Tripodi, et al., 2004).However, the subjectively rated
ability of one collagen binding assay, the ristocetin cofactor assay and the SDS agarose
electrophoresis and immunoblotting of degraded multimers of VWF substrate was excellent
and the ability of a second collagen binding assay was subjectively rated as good (Tripodi, et
al., 2004). The only method that directly evaluated ADAMTS13 protease activity was the
SDS-PAGE and quantitative immunoblotting of a recombinant VWF polypeptide including the
A1-A2-A3 domains of VWF. For the latter assay, the linearity (r2=0.77) between expected and
observed results and ability to detect severe ADAMTS13 deficiency were acceptable,
however these results were no better than that of the other methods which indirectly assess
VWF cleavage (Tripodi, et al., 2004).
The only method using ULVWF multimers (the likely physiological substrate for ADAMTS13)
as a substrate (SDS-agarose and immunoblotting), had a high detection rate for 0%
ADAMTS13 levels. Further methodological improvement is required in terms of the
reproducibility and the linearity (r2=0.39) of the expected and the observed results (Tripodi, et
al., 2004).
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There is poor agreement between the results obtained on plasma samples with intermediate
and normal ADAMTS13 levels with different methods (Tripodi, et al., 2004). This may be
improved to some extent with the use of a common standard to construct calibration curves.
The use of different standards did not appear, however, to be a main determinant of the
variability between laboratories. High variability was noted even for different laboratories
employing the same techniques for ascertaining ADAMTS13 levels (Tripodi, et al., 2004).
Thus, the inter-laboratory variability may be due to the way in which the different laboratories
have set up the same technique rather than due to differences between techniques (Tripodi,
et al., 2004).
Tripodi and co-workers conclude that a varied performance of the methods is noted, the
results by Studt and co-workers are extended and confirmed, and an overall optimistic view of
the reliability of currently available methods for ADAMTS13 detection is supported (Tripodi, et
al., 2004). Tripodi and co-workers recommend further multicentre clinical studies to further
assess and clarify the role of assaying ADAMTS13 levels with respect to management of
patients with thrombotic microangiopathies (Tripodi, et al.,2004). The subsequent more recent
assays for assessing ADAMTS13 activity including the Enzyme-Linked Immunosorbent Assay
using recombinant VWF-A2 domain as a substrate used by Whitelock et al, and Zhou et al,
and the FRETS-VWF73 assay used by Kokame et al, have not yet been compared in a
multicentre trial (Whitelock, et al., 2004; Zhou & Tsai, 2004; Kokame, et al., 2005).
65
2. Study Objectives
 To establish a practical assay for VWFCP activity for routine use in our laboratory.
The rapid collagen binding ELISA assay based on Rick and co-workers, and Aronson
and co-workers, was selected (Aronson, Krizek & Rick, 2001; Rick, et al., 2002).
 To measure VWFCP activity using a group of HIV negative controls and two HIV
positive groups, those with normal platelet counts and those with thrombocytopenia
(of any cause except TTP), in order to establish cut-off values for normal VWFCP
activity in these groups and to assess any significant differences between groups in
patients from our local setting.
 The diagnostic utility of assessment of VWFCP activity in patients with HIV related
TTP, would depend on the outcome of the above investigation.
Should a wide range of VWFCP activity be found in HIV positive patients (particularly
comparing those with low platelet counts versus normal platelet counts), the assay is unlikely
to be of diagnostic utility in the individual HIV positive patient, where levels of VWFCP may be
altered in the absence of TTP (Reiter, et al., 2003; Mannucci, et al., 2001).
However, should VWFCP activity in unselected patients with HIV and thrombocytopenia be
found to fall generally within the normal range, or if a specific cut-off value can be established
for HIV positive patients in general (regardless of platelet count), then further investigation
into levels in patients with HIV related TTP would be warranted and patients with HIV and
TTP would be assessed using this assay.
Endpoints of study
The study will have been completed once the assay has been established and sufficient
samples have been analysed to determine the range of VWFCP activity in HIV positive
patients with and without thrombocytopenia.
However, depending on the outcome of the initial assessments, further assessment of
VWFCP activity in patients with HIV-related TTP would be performed.
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3.. Materials and Methods
3.1 Specimen collection
The study was a prospective observational study.
Study samples were obtained from Johannesburg General Hospital and Helen Joseph
Hospital.
 Samples from HIV negative control patients with normal platelet counts (Group 1),
were collected from consecutive patients attending the Coagulation/INR clinic at
Johannesburg General Hospital.
 Samples from HIV positive patients with both normal platelet counts (Group 2) and
low platelet counts but without TTP (group 3), were collected from consecutive
patients attending the HIV / ARV (Anti-RetroViral) clinic at Helen Joseph Hospital.
 Samples from HIV positive patients with TTP (prior to the start of plasma therapy)
were collected from consecutive patients presenting at the Johannesburg General
Hospital or Helen Joseph Hospital between November 2003 and December 2005
(n=20).
Summary of Inclusion criteria:
Group 1: HIV negative, normal platelet count (n=77)
Group 2: HIV positive, normal platelet count (n=74)
Group 3: HIV positive, low platelet count (platelet count less than 100 x10^9/l) (n=58)
Patient groups seen at the above-mentioned clinics were identified by review of the laboratory
data available on DISA (the hospital computer system). The number of patients chosen was
based on logistical constraints.
Venous blood samples taken for routine purposes in citrated tubes were utilised, with
informed consent. Samples were processed anonymously with a laboratory number. Once the
samples were collected, they were centrifuged and the plasma taken off. The Plasma was
stored at -70 ºC.
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Ethics approval and informed patient consent were obtained. HIV positive patients were
known patients who were aware of their HIV status and who were attending the ARV-clinic.
All patients were confirmed to be HIV positive or negative by enzyme-linked immunosorbent
assay.
Minimum diagnostic criteria for TTP were thrombocytopenia (platelet count < 100X109/l),
microangiopathic haemolytic anaemia and high serum lactate dehydrogenase levels with no
other identifiable cause (Moake, 2002). In each case the presence of red cell fragments and
thrombocytopenia was confirmed by a haematopathologist. Coagulation studies to exclude a
DIC were performed on all patients at presentation as well as serum chemistry to assess
renal function. The presence of opportunistic infections or HIV-associated malignancies were
excluded as far as possible by the treating clinician, using clinical examination with serology,
radiological imaging and microbiological or histological assessment where appropriate. None
of the 20 patients were on antiretroviral therapy at the time of presentation. Patients were
treated at the discretion of the managing physician. Therapy was commenced immediately
after diagnosis and the majority of patients were treated with daily therapeutic plasma
exchange.
3.2 Overview of the principles of the collagen binding assay
The collagen binding assay used by Rick and co-workers, and Aronson and co-workers, was
set up in this study (Aronson, Krizek & Rick, 2001; Rick, et al., 2002). This is an ELISA-based
assay where the microtitre plate well is coated with collagen. Any remaining sites on the
microtitre plate are blocked with blocking agent. Both undialysed and dialysed (this serves to
“activate” VWFCP which cleaves VWF) patient sample is added to the microtitre plate. The
patient’s VWF binds the collagen covering the microtitre well surface. The wells are then
washed, and horseradish peroxidase labelled anti-VWF antibody is added. Another wash step
is performed, and substrate (ABTS TM) is added which is enzymatically converted to product.
The increase in absorbance is then measured spectrophotometrically at 405nm.
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The dialysed absorbance reading is divided by the undialysed absorbance reading and the
value is multiplied by 100 to give a percentage of Residual Collagen Binding Activity (RCBA
%). See section 3.3 on interpretation of results for more information in this regard.
In 1983, Santoro, described the preferential binding of high molecular weight multimers of
VWF to fibrillar collagen (Santoro, 1983). Santoro, documented that high molecular weight
forms of VWF bind even at low collagen concentrations, high and intermediate molecular
weight forms of VWF bind at high collagen concentrations and very low molecular weight
forms of VWF do not bind even at high collagen concentrations (Santoro, 1983). Therefore
higher molecular weight forms of VWF have a greater affinity for fibrillar collagen and under
conditions where the concentration of collagen is limiting, there is preferential binding of the
higher molecular weight forms of VWF (Santoro, 1983).
The latter finding explains the underlying principle of the ELISA-based collagen binding
assay, whereby the undigested high molecular weight multimers of VWF that have not been
cleaved by activated VWFCP (during the dialysis step), then bind to the collagen on the
microtitre plate (low collagen concentrations used 3μg/ml). The ratio of the dialysed to the
undialysed sample is then used to assess for the % residual collagen binding activity which is
indirectly proportional to the VWFCP activity.
This assay therefore functions due to the preferential binding of high molecular weight VWF
multimers (Favaloro, Facey & Grispo, 1995; Ramasamy, et al., 1998; Fischer, et al., 1996;
Fischer, Thomas & Dorner, 1998; Casonato, et al., 1997).
Optimal conditions were established for this assay in our laboratory which concurred with
those used by Rick and co-workers. The use of low concentration collagen in our assay
(3μg/ml) results in preferential binding of the high molecular weight multimers as documented
in the literature (Santoro, 1983).
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Vitrogen TM Collagen was used, which is an ultrapure purified bovine Type I Collagen, as used
by Rick and co-workers, for the purposes of VWFCP activity (as measured by % residual
collagen binding activity). The use of other different types of collagen was not explored in this
study. This would be a costly exercise and there is documented successful use of Vitrogen TM
Collagen by Rick and co-workers, upon which this assay is based. Of note is that subsequent
to this study, the manufacturer of Vitrogen TM Collagen is apparently no longer in business
and the replacement is PureColTM which is apparently identical to Vitrogen TM Collagen
(http://www.vitrogen.nl/). This collagen replacement has not as yet been used in our
laboratory setting.
3.3 Interpretation of the rapid collagen binding assay results
The cut-off values for % RCBA indicated here are as per Rick and co-workers, this study
established our own cut-off values which are discussed in section 4. See Figure 5, 6 and 7 for
a schematic depiction and explanation of the reaction in the microtitre well. The absorbance
reading of the microtitre plate reflects the collagen binding activity of the sample. Each
sample was run in duplicate. The average dialysed absorbance reading was divided by the
average undialysed absorbance reading and multiplied by 100 to give a percentage. This
value is termed % RCBA.
The % RCBA is inversely related to the VWFCP activity. % RCBA above the cut-off value
translates to reduced VWFCP activity (VWFCP deficiency) and % RCBA below the cut-off
value translates to a normal VWFCP activity.
Normal VWFCP activity leads to a decrease in collagen binding by VWF, due to a decrease in
the high molecular weight multimers of VWF (VWFCP cleaves these high molecular weight
multimers). Dialysis of the sample serves to “activate” the VWFCP, therefore the dialysed
reading reflects RCBA post VWFCP activation.
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The dialysed sample reading should be lower than the undialysed sample reading (undialysed
sample has not been exposed to VWFCP activity) which will have more high molecular weight
multimers of VWF which bind to collagen resulting in a higher reading. Therefore the normal
ratio according to Rick and co-workers, should be less than 33% (Rick, et al., 2002).
As per Rick et al., a ratio of >33%, reflects reduced VWFCP activity which comes about as a
result of increased binding of high molecular weight VWF multimers which have not been
cleaved by VWFCP (either due to a deficiency of VWFCP or an autoantibody to VWFCP). In
this setting, the dialysed reading is not lower than the undialysed or baseline reading and a
greater ratio is achieved (>33%).
 Normal VWFCP activity detected by ratio:
(Residual CBA) Dialysed absorbance reading < 33% *
(CBA at t=0) Undialysed absorbance reading
 Decreased VWFCP activity detected by ratio
(Residual CBA) Dialysed absorbance reading > 33% *
(CBA at t=0) Undialysed absorbance reading
* Calculation and cut-off values as per Rick, et al., 2002. This MMED study established our
own cut-off values in our laboratory.
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Figure 5. Schematic representation of the VWF binding ELISA assay. The microtitre plate
well is coated with collagen. Any remaining sites on the microtitre plate are blocked with
blocking agent. When the patient sample is added to the microtitre plate well, the patient’s
VWF binds the collagen covering the well surface. The wells are then washed, and
horseradish peroxidase labelled anti-VWF antibody is added. Another wash step is
performed, and substrate (ABTS TM) is added which is enzymatically converted to product.
The increase in absorbance is then measured spectrophotometrically at 405nm.
Substrate
Product
Horseradish peroxidase labelled antibody
Von Willebrand factor
Collagen
Blocking agent
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Figure 6. Schematic representation of microtitre plate well with normal VWFCP activity.
Under normal circumstances, when there is no deficiency of VWFCP, the VWF is cleaved by
the VWFCP which leaves less VWF remaining capable of binding to the collagen on the
microtitre plate well. This results in a dialysed: undialysed ratio of RCBA below the cut-off
value.
Figure 7. Schematic representation of microtitre plate well with deficient VWFCP activity.
When a deficiency of VWFCP exists, such as in TTP, less VWF is cleaved by the VWFCP,
leaving more VWF to bind to the collagen coating the microtitre plate well. This results in a
dialysed: undialysed ratio of RCBA above the cut-off value.
Please refer to Figure 8 for a flow diagram of the laboratory methods of the rapid collagen
binding assay (as per Rick, et al., 2002).
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3.4 Flow Diagram of assay procedure
Patient Sample
Tube 1: Tube 2:
Test plasma dialysed Undialysed baseline
in urea for 3 hours plasma
Diluted in buffer Diluted in same buffer
Place diluted samples on a microtitre plate
(coated with collagen and blocked)
Incubate plates for 1 hour at room temperature and then wash plates
Add Horseradish peroxidase-labelled anti-human
VWF to the plates and incubate for 1 hour
Wash plates
Develop plates in the presence of a chromogen
Read plates kinetically at 405nm on a microtitre plate reader
Results expressed as: Residual CBA
CBA at t = 0
>33% means VWFCP <33% means VWFCP
activity is low * activity is normal *
Figure 8. Flow diagram of the residual collagen binding assay laboratory methods (as
per the method described by Rick, et al., 2002). * % RCBA cut-off as established by Rick,
et al., 2002.
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Explanation of the flow diagram of the assay procedure
The assay used, is as per Rick and co-workers, who developed a simple rapid assay for
the detection of VWFCP activity based on the collagen binding properties of VWF. The
assay does not require specialized reagents and can be completed within 8 hours (Rick,
et al., 2002). The plasma of the patient is used as both the source of the enzyme and the
substrate, negating the need for purified VWF or other preparation of normal plasma VWF
(Rick, et al., 2002; Aronson, Krizek & Rick, 2001). Test plasma (approximately 0.5ml) is
dialysed for 3 hours in urea (which facilitates the VWFCP with proteolytic cleavage of
VWF multimers) and is then diluted in buffer.
Undialysed plasma samples are diluted in the same buffer. The diluted samples are then
placed on a microtitre plate, previously coated with 3µg/ml of collagen and blocked.
After a 1hour incubation period at room temperature, the plates are washed and
horseradish peroxidase-labelled anti-human VWF is added to the plate and incubated for
1 hour. The plates are then washed, developed in the presence of a chromogen and read
kinetically at 405nm on a microtitre plate reader. Results are then expressed as the
(dialysed) residual collagen binding activity (CBA) divided by the (undialysed) baseline
CBA (at t = 0).
Clinical utility would probably involve providing a result indicating either a normal or
decreased protease activity, rather than a quantitative result.
A normal level of protease activity leads to a decrease in collagen binding by VWF due to
a decrease in the high molecular weight multimers of VWF (VWFCP cleaves these high
molecular weight multimers). Only VWF which has not been sufficiently cleaved by
VWFCP, will bind to the collagen coated microtitre plates. Reduced VWFCP activity
results in increased collagen binding of VWF multimers, as they are not proteolytically
cleaved by VWFCP (either due to a deficiency of VWFCP or autoantibody).
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3.5 Assay development
Refer to Figures 9, 10, 11, 12 and 13 for photographs of some of the laboratory equipment
used.
3.5.1 Buffer Preparation
Buffers were prepared as follows:
Collagen Buffer: To Prepare 500mls:
 3,0285g Tris; 2,922g NaCl
 Distilled Water was added up to 300mls at first as HCL needs to be added to
achieve a pH of 7,4, thereafter more distilled water could be added up to a total
volume of 500mls.
 50µl was used per well therefore 5mls of this buffer was required per microtitre plate.
Sample/Dilution Buffer: To prepare One Litre:
 3,0285g Tris; 2,922g NaCl; 1000μl Tween
 Distilled Water was added up to one litre, but pH of 7,4 was required before the full
volume was added.
 The end of the pipette tip was cut off when working with Tween due to its viscosity.
-this buffer was used for dilution of patient samples and antibody solution.
Reaction/Dialysis Buffer: To Prepare One Litre:
 0,6057g Tris; 1000μl Tween
 90,75g Urea-Distilled Water was added up to one Litre, but a pH of 8,3 was required
before full volume was added.
Wash Buffer: To Prepare One Litre:
 6,057g Tris; 5,844g NaCl; 1000μl Tween
 Distilled Water was added up to One Litre but a pH of 7,4 was required before full
the volume is added.
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Phosphate Buffered Saline:
 A prepared tablet form was used, dissolved in 100mls distilled water and mixed with
a magnetic stirrer (PBS Dulbecco A 100 tablets from C A MilchTM).
3.5.2 Preparation of Collagen-coated and blocked microtitre plates
 Collagen Solution was made up per number of plates required at 50 µl per well,
using Collagen buffer with Vitrogen TM Collagen: from Ilex Medical Systems TM
(stored in fridge) at a concentration of 3µg/ml. A concentration of 3µg/ml Collagen is
required, per plate (50µlx96wells =5mls), therefore the total amount of collagen
required was 15µg (5mls x 3µg). One µl of Vitrogen TM Collagen is equivalent to 3µg
of Vitrogen TM Collagen. Therefore per microtitre plate: 5µl Vitrogen TM Collagen was
required per 5mls collagen buffer to have a collagen concentration of 3µg/ml.
 Once the above collagen solution was prepared, 50µl of this solution was pipetted
into each well and incubated for one hour at room temperature on a rocker. ELISA
plates used: from NUNC TM: Immunomodule F16 Maxisorp. Therefore for running of
patient samples, a full 96 well plate does not have to be used (F16 individual strips
placed in NUNC TM frames).
 The plates were washed 3 times with Wash buffer (using multichannel pipette at
200µl per well).
 Blocking agent was prepared to block the microtitre plates. Superblock TM Dry Blend
Blocking Buffer in TBS (from Pierce TM, 37545) was used. Each pouch of dry
Superblock TM was reconstituted (make sure completely dissolved) with 200 mls
distilled water just before use.
 200µl of the above blocking solution was pipetted into each well. The plate was
immediately emptied by inversion. This step was repeated twice.
 The plates were washed 3 times in Wash buffer.
 Storage:
-Phosphate Buffered Saline (PBS) was added at 200µl per well to fill up the wells
so as to prevent them from drying out.
-Plates were covered with Parafilm/ NUNC TM sealing tape.
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-Plates were placed in plastic packet labelled with date and content (stored
upright).
-Stored at 4 ºC in the fridge overnight (can be stored for 4 weeks).
3.5.3 Sample Preparation and Dialysis
 The baseline patient plasma samples were Barium Chloride exposed which
“activated” the VWFCP enzyme in the sample prior to dialysis in urea (in
reaction/dialysis buffer). Mild denaturing conditions with urea and exposure to Barium
Chloride promoted VWFCP interaction with VWF (Tripodi, et al., 2004). ADAMTS13
requires divalent metal ions for proteolytic activity (Kokame, et al., 2005) such as Ba2+
or Ca2+ ions.
To make up 50mls Barium Chloride solution the following was used:
One part BaCl2 to 9 parts collagen coating buffer:
1.1g BaCl2 up to 50mls with collagen coating buffer.
120uls baseline patient plasma taken and 12ul of the BaCl2 solution added. Incubated
for 5 minutes and then proceeded with the assay where 50ul of the sample was
dialysed and the remainder was left at room temperature (undialysed sample).
 60µl of each sample was placed in a minidialysis unit: Slide-A-Lyzer MINI-Dialysis TM
units 10,000 MWCO from Separations TM used (label each sample), inserted into the
floater and immersed in approximately 100mls (although Rick and co-workers
suggest one litre of reaction/dialysis buffer, however, we used a smaller container.
 The volume of bath to sample should be >30:1 of reaction/dialysis buffer which was
prewarmed to 37 ºC in a sealed glass beaker/container in a water bath. These
samples were dialysed for three hours in the above mentioned sealed
beaker/container which was placed in the waterbath (which should remain at 37 ºC).
 Dialysis for 3 hours in a buffer containing urea facilitates partial VWF unfolding to
expose the cleavage site at Tyr 842 – Met 843 in VWF multimers (Furlan & Lämmle,
2001). Hypotonic salt solution, urea, guanidium chloride or shear stress cause
conformational change in the VWF molecule, thereby exposing the cleavage site
(Furlan & Lämmle, 2001).
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 The undialysed samples remained at room temperature during this time.
 1:20 dilutions of both the dialysed and undialysed samples were prepared, using
sample plasma and sample/dilution buffer.
1:20 dilution: 50µl patient sample and 950µl sample/dilution buffer.
buffer (each undialysed and each dialysed sample were run in duplicate on the
microtitre plate).
 50µl of the 1:20 of both the dialysed and undialysed sample were added to the each
microtitre well and this was performed in duplicate.
3.5.4 Addition of samples to Microtitre Plate
 Refer to Table 2 and Table 3 which show the numbering of 96 well ELISA plate.
 Undialysed samples (50µl/well) were run in rows A, C, E and G with 1:20 dilutions
(each in duplicate). 20 patient samples could be run per 96 well microtitre plate (as 8
wells were used for both dialysed and undialysed normal pool control sample, 4 wells
were used for background antibody and substrate and 4 wells were used for
background substrate, see below).
 Dialysed samples (50µl/well) were run in rows B, D, F and H with 1:20 dilutions (each
sample run in duplicate).
 A1, A2, G11, G12, were used for only Antibody and substrate (which are added at a
later stage) and no patient sample was added to these wells.
 At this point in time only PBS is added to these wells (50ul/well).
 B1, B2, H11, H12 were used for only Substrate (which is added at a later stage) and
no patient sample was added to these wells.
At this point in time only PBS was added to these wells (50ul/well).
 Undialysed normal pool control sample was added to wells C1, C2, E11, E12.
Dialysed normal pool control sample was added to wells D1, D2, F11, F12.
 Samples were incubated in the microtitre plate for one hour at room temperature, on
a rocker.
 The microtitre plate was washed 3 times with Wash buffer.
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3.5.5 Addition of Peroxidase-labelled Anti-human Von Willebrand Factor
Antibody to microtitre plate
 Peroxidase-labelled Anti-human Von Willebrand Factor (VWF) antibody: Rb a Hu Von
Willebrand Factor / HRP 2ml from Diagnostech TM (stored in fridge) was added to the
microtitre plate at a 1:400 dilution.
92 wells require antibody (the remaining 4 wells have substrate only) at 50µl per well
(made up a little extra though, therefore for 96 wells per plate) 96 x 50 = 4800µl
antibody solution was required.
For a 1:400 dilution of the antibody for one microtitre plate:
Required 12µl of antibody and 4788µl buffer (Use sample buffer).
 50µl of the above antibody solution was added to each well, except B1, B2, H11, H12
which would only have substrate added at a later stage (these wells were filled with
only Phosphate Buffered Saline at 50µl/ well at this point in time).
 Incubated for one hour at room temperature on a rocker.
 Washed plate 3 times with Wash Buffer.
3.5.6 Addition of Substrate to Microtitre Plate
 One substrate tablet was added (ABTSTM tablets from RocheTM catalogue number:
1204521. 5mg x20 tablets, light sensitive and stored in fridge), to 5mls of commercial
substrate solution (Buffer for ABTS TM from Roche TM catalogue number: 1204530
125ml, also stored in fridge) in a test tube and immediately covered with foil. This was
stored in a dark cupboard while the tablet was dissolving.
 50µl of the above substrate solution was added to each well, using the multichannel
pipette (this is quicker as the substrate is light sensitive). Allowed for slightly more
than 5mls of the above solution per plate.
 Incubated the microtitre plate in a dark cupboard for 30 minutes.
 Read the plate on a Microtitre Plate Reader at precisely 45 minutes (at 405nm
wavelength). 30 minute absorbance readings were also taken for comparison,
however the 45 minute absorbance readings were used.
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 Divided dialysed absorbance reading by undialysed absorbance reading and
multiplied by 100 to obtain percentage RCBA . As each sample is run in duplicate, the
average of the two readings were used.
Table 2. Depiction of numbering of 96 well ELISA plate for addition of patient sample.
A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12
B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 B11 B12
C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 C12
D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11 D12
E1 E2 E3 E4 E5 E6 E7 E8 E9 E10 E11 E12
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12
G1 G2 G3 G4 G5 G6 G7 G8 G9 G10 G11 G12
H1 H2 H3 H4 H5 H6 H7 H8 H9 H10 H11 H12
Table 3. Depiction of sample placement per 96 well ELISA plate. Ab+S indicates Antibody
and Substrate only; S indicates Substrate only; NPu indicates Normal Pool Undialysed; NPd
indicates Normal Pool Dialysed; P1u-P20u indicates Patient sample 1-20 Undialysed; P1d-
P20d indicates Patient sample 1-20 Dialysed.
Ab+S Ab+S P3u P3u P7u P7u P11u P11u P15u P15u P19u P19u
S S P3d P3d P7d P7d P11d P11d P15d P15d P19d P19d
NPu NPu P4u P4u P8u P8u P12u P12u P16u P16u P20u P20u
NPd NPd P4d P4d P8d P8d P12d P12d P16d P16d P20d P20d
P1u P1u P5u P5u P9u P9u P13u P13u P17u P17u NPu NPu
P1d P1d P5d P5d P9d P9d P13d P13d P17d P17d NPd NPd
P2u P2u P6u P6u P10u P10u P14u P14u P18u P18u Ab+S Ab+S
P2d P2d P6d P6d P10d P10d P14d P14d P18d P18d S S
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Figure 9. Photograph of some of the laboratory equipment used.
Figure 10. Photograph of NUNC TM ELISA plates and minidialysis float TM.
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Figure 11. Photograph of NUNC TM ELISA immunomodules and frames used.
Figure12. Photograph of Slide-A-Lyzer TM Minidialysis float and minidialysis units.
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Figure 13. Photograph of minidialysis float TM immersed in dialysis buffer prior to placement in
a waterbath at 37 ºC for 3 hours.
3.5.7 Mixing Studies
This is a modification of the assay which was used to evaluate the presence of an inhibitor to
VWFCP activity. Samples of plasma from patients with high % RCBA (i.e. low VWFCP
activity) were mixed with equal volumes of pooled normal plasma (confirmed to have normal
enzyme activity) and incubated at room temperature for 30 minutes prior to the dialysis step.
Correction of the % RCBA back into the normal range due to activity of the added protease
from a documented normal pool control sample was taken to indicate absence of an inhibitor.
Conversely, persistent elevation of the % RCBA suggested the presence of an antibody
inhibitor limiting the activity of the added extrinsic protease from the control sample.
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3.6 Quantitation of Von Willebrand Factor antigen levels in patients with TTP and HIV
(Group 4)
Quantitative determination of VWF antigen levels was done on the same citrated plasma
samples collected before therapy from each patient. A commercial automated latex enhanced
immunoassay was used for the quantitative determination of VWF antigen in citrated plasma
on IL Coagulation Systems. VWF antigen levels are reported in % of normality.
3.7 Statistical analysis
Statistical programmes used include SAS Version 9.1 and STATA Version 9.
Statistical significance was assessed at the 5% level.
Non-parametric procedures namely the Kruskal-Wallis test and the Wilcoxon rank-sum test
were used to assess the three patient groups:
The Kruskal-Wallis test was used to compare the three groups (Group 1, Group 2, Group 3).
The Wilcoxon rank-sum test was then used to do pair-wise comparisons of these groups
(Group 1 versus Group 2; Group 1 versus Group 3; Group 2 versus Group 3).
Analysis of Variance was used to assess and compare the background non-specific binding
of antibody and Substrate reactions between ELISA plates.
To find correlations, Pearsons and (Spearmans) Rank correlations were used which are
parametric and non-parametric procedures respectively.
The null hypothesis Ho states: There are no statistically significant differences between the 3
patient groups (Group 1= Group 2= Group 3). The alternate hypothesis H1 states: There is at
least one statistically significant difference between the various pairs of the 3 groups
(p=0.0001).
Our Data will be visualized according to a plot of “% Residual Collagen Binding Activity” on
the vertical axis and various patient groups on the horizontal axis.
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4. Results
4.1 Summary of established optimal conditions for the ELISA
Refer to Table 4 which lists the parameters that were optimised for the ELISA. Further detail
regarding optimisation is discussed further in the following section.
Table 4. Summary of the parameters that were optimised for the ELISA
Parameter Optimisation step Not Optimal
Patient samples Citrated patient samples Red top tubes (no additive)
Collagen concentration 3μg/ml for coating ELISA plate 4μg/l, 5μg/l, 6μg/l
Blocking agent Superblock ™ Dry Blend Casein
ELISA plate NUNC TM immunomodule ELISA
plates & frames (batching samples)
Full ELISA plates
Patient sample dilution 1:20 (run in duplicate) 1:40
Primary antibody dilution 1:400 1:100, 1:200, 1:1000
Incubation times One hour with patient samples and
anti-VWF antibody
45 minutes
Reading ELISA plate 45 minutes after loading substrate 30 minutes, 60 minutes
Control Normal pooled plasma as a
standard for the ELISA plate
4.1.1 Blocking of ELISA plates
The ELISA plates used by Rick and co-workers were pre-blocked. As pre-blocked plates
could not be sourced and for cost-effectiveness, our own microtitre plates were blocked.
Superblock ™ Dry Blend was compared to Casein (0.5g) as blocking agents.
Casein (0.5g) was made up 100 mls in both PBS and TBS/wash buffer and 200ul was
pipetted into each microtitre well, incubated for various times ranging from 15 minutes to one
hour.
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As indicated in the section 3, each pouch of dry Superblock TM was reconstituted (making
sure it was completely dissolved) with 200 mls distilled water just before use. 200µl of the
above blocking solution was pipetted into each well. The plate was immediately emptied by
inversion. This step was repeated twice.
Overall the use of Casein was not found to be successful compared to Superblock ™.
Refer to Appendix D for data obtained for ELISA plates blocked with Superblock ™ Dry Blend
versus Casein (0.5g). The % RCBA values were overall greater for ELISA plates blocked with
Casein with lower absorbance readings for both Undialysed and Dialysed samples. The
background antibody and substrate and background substrate readings were however
comparable for ELISA plates blocked with both Superblock ™ versus Casein. With the use of
Casein, the higher RCBA percentages were due to the smaller difference between the
Undialysed absorbance reading and the dialysed absorbance reading. Superblock ™ Dry
Blend was therefore elected for use in this study.
In a split sample comparison of thirty eight samples, plates blocked with Superblock TM
compared to plates blocked with Casein as a blocking agent showed a mean % RCBA of
33.12% versus 43.9% respectively. This indicated that Superblock TM was a more effective
blocking agent.
4.1.2 Background non-specific binding
Background Antibody and Substrate reaction
The background Antibody and Substrate reaction was assessed in four microtitre wells per
ELISA plate where only peroxidase-labelled Anti-human Von Willebrand Factor (VWF)
antibody (Rb a Hu Von Willebrand Factor / HRP 2ml from Diagnostech TM) and subsequently
Substrate was added with no addition of patient sample. Please refer to section 3 for further
detail.
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Established the background non-specific binding (Antibody + Substrate) absorbance readings
with a mean value of =0.12, a minimum value of 0.11 and a maximum value of 0.13 (standard
deviation=0.01). The 95% Confidence Interval for background non-specific binding is noted to
be 0.118 to 0.124.
Using analysis of variance (ANOVA) no statistically significant difference was noted for the
background antibody and substrate reactions between 13 ELISA plates (p=0.0825).
Background Substrate reaction
The background Substrate reaction was assessed in four microtitre wells per ELISA plate
where only Substrate was added with no addition of patient sample or peroxidase-labelled
Anti-human VWF antibody. We established the background substrate reaction with a mean
value of 0.074, a minimum value of 0.069 and a maximum value of 0.08 (standard
deviation=0.003).
4.2 Troubleshooting the Assay
The data from 2 ELISA plates were excluded, as the background non-specific binding of
antibody and substrate was higher on these plates (0.1855 and 0.173 respectively). Thus
instead of n=77 for Group 1, n=70, as 7 samples were excluded and instead of n=74 for
Group 2, n=55, as 19 samples were excluded. However statistical analysis performed
comparing the 3 patient groups before exclusion of these samples, revealed the same
statistical end-points, however the % RCBA cut-off values for Group 1: was 1.41% higher at
38.53%, Group 2: was 1.86% higher at 52.04%, Group 3: was the same at 50.88%
The combined % RCBA cut-off value for Group 2 and Group 3 was 0.95% higher at 51.46%
with inclusion of the data from the 2 excluded plates.
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4.3 Reproducibility of assay
Inter-assay Reproducibility
Normal pool sample was run in quadruplicate on each ELISA plate and this data were used to
assess the reproducibility of the assay. The inter-assay coefficient of variation is 8.80%.
For the normal pool sample, the interassay % RCBA ranged from a minimum of 24% to a
maximum of 31.57% with a mean of 27.44%.
Intra-assay reproducibility
The data of normal pool sample run in quadruplicate on each ELISA plate were also used to
assess intra-assay reproducibility. This revealed a coefficient of variation of 4.83%. As this is
a manual technique, the variability may be related to pipetting error.
4.4 Data for HIV negative controls, HIV positive patients with normal platelet counts
and low platelet counts
To establish whether the collagen binding assay would be of clinical utility in the setting of
HIV, results of percentage RCBA in HIV positive (both low platelet counts and normal platelet
counts) and HIV negative patients (with normal platelet counts) were compared. Results are
given in percentage (absorbance readings of dialysed/ undialysed x 100) of RCBA. Group 1
constitutes HIV negative patients with normal platelet counts, Group 2 constitutes HIV positive
patients with normal platelet counts and group 3 constitutes HIV positive patients with low
platelet counts.
We established our own cut-off value for % RCBA in both HIV positive and HIV negative
patients. The upper limit or cut-off of % RCBA for each group was established by the mean
plus 2 standard deviations as per Rick and colleagues (Rick, et al., 2002).
In Group 1 (HIV negative patients with normal platelets), the % RCBA cut off value we
obtained is 37.12%, which is comparable to the cut-off value used by Rick and co-workers
(33.02%).
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In group 2 (HIV positive patients with normal platelets), the cut-off value we obtained is
50.18% and in group 3 (HIV positive patients with low platelets), a similar cut-off value of
50.85% is noted.
The combined cut-off for the HIV positive patients with both normal and low platelets (Group 2
and Group 3) was 50.51% which is higher than that for HIV negative controls (Group 1).
Please refer to Table 5 for the standard deviation values used to calculate the cut-off values.
Figure 14 depicts a box and whisker plot of the 3 groups which illustrates the higher % RCBA
in the setting of HIV (Group 2 and Group 3).
Statistical analysis using the Kruskal-Wallis test and Wilcoxon rank-sum test showed a
significant difference between Group 1 and Group 2 (p=0.0001) and between Group 1 and
Group 3 (p=0.0006). However, there was no significant difference between Group 2 and
Group 3 (p=0.7783). Refer to Table 7 for a summary of this information.
Table 5. Depiction of % Residual Collagen Binding Activity data from 3 groups of patients
Group Number Mean Median Minimum Maximum SD cut-off
1 70 27.06% 26.97% 17.79% 38.62% 5.03% 37.12%
2 55 33.02% 30.45% 17.19% 55.12% 8.59% 50.18%
3 58 32.41% 30.55% 14% 55.24% 9.22% 50.85%
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Figure 14. Box-plots of % Residual Collagen Binding Activity (RCBA) for 3 patient groups:
Group 1: HIV negative control patients;
Group 2: HIV positive patients with normal platelet counts;
Group 3: HIV positive patients with low platelet counts.
The % RCBA cut-off values are inversely related to the VWFCP activity. In HIV negative
patients (Group 1), a result of less than 37.12% indicates normal VWFCP activity and a result
greater than 37.12% reflects reduced VWFCP activity. In HIV positive patient groups
regardless of the platelet count (Group 2 and Group 3), a result of less than 50.51% indicates
normal VWFCP activity and a result above 50.51% indicates reduced VWFCP activity. The
latter is depicted in Table 6.
Table 6. Depiction of % Residual Collagen Binding Activity cut-off value in HIV negative
(Group 1) versus average for HIV positive (Group 2 and Group 3) patients and interpretation
of Von Willebrand Factor Cleaving Protease (VWFCP) activity.
Group 1: HIV negative Group 2 & 3: HIV positive
% RCBA cut-off 37.12% 50.51%
Normal VWFCP activity Less than 37.12% Less than 50.51%
Reduced VWFCP
activity Greater than 37.12% Greater than 50.51%
Group
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The Shapiro-Wilk test of normality revealed the data for Group 1 to be normally distributed
(p> 0.05), the data for Group 2 is not normally distributed (p< 0.05) and the data for Group 3
is noted to be normally distributed (p> 0.05).
The data for Group 2 could be normalised on log-transformation and parametric analysis
could therefore be applied to all groups. Student’s T-test revealed that the level of significance
remained unchanged, compared to Wilcoxon-rank sum, for the group to group comparisons
as assessed by p-value. This therefore confirmed the trueness in the analysis of this data.
Refer to Table 7 for a summary of this data.
Table 7. Summary of p-values for Group comparisons
Pair Student’s T-test Wilcoxon rank-sum Significance
Group 1 vs Group 2 p=0.0001 Different
Group 1 vs Group 3 p=0.0006 Different
Group 2 vs Group 3 p=0.7783 Same
Log-Group 1 vs Log- Group 2 p=0.000004 Different
Log-Group 1 vs Log- Group 3 p=0.00029 Different
Log-Group 2 vs Log- Group 3 p=0.7136 Same
4.5 Data for twenty HIV positive patients with TTP (Group 4)
Using this assay, a specific cut-off value could be established for HIV positive patients in
general (regardless of platelet count), and further investigation into VWFCP levels in patients
with HIV related TTP was warranted. Samples from twenty HIV positive patients with TTP
were assessed using this assay and these patients constitute Group 4.
Table 8 shows the laboratory findings at presentation in the latter patients as well as the
results and interpretation of the collagen bonding assay and mixing studies. The mixing
studies are a modification of the collagen binding assay which was used to evaluate the
presence of an inhibitor to VWFCP activity in patients with a high % RCBA.
Of the 20 patients, 6 (30%) had normal VWFCP activity (<50.5% RCBA). One patient had a
borderline normal result of 51.2% which was included in the normal VWFCP activity group as
the other 14 patients (70%) had severely reduced activity (as indicated by >90% RCBA).
Loss of the plasma sample precluded assessment of inhibitors in one patient. Of the
remaining 13 patients with severely reduced VWFCP activity, 8 (62%) had no inhibitors (%
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RCBA within normal range post mixing) while 5 (38%) had a definite inhibitor. Refer to Table
9 for a summary of this data.
VWF antigen levels were high in all patients but the majority of the patients with severely
reduced VWFCP activity had higher levels than patients with normal/ borderline VWFCP
activity and this achieved statistical significance.
Table 8. Laboratory Data of 20 HIV positive patients with Thrombotic Thrombocytopenic
Purpura (TTP). CD4 indicates CD4 count; Hb, haemoglobin; LDH, lactate dehydrogenase;
INR, international normalized ratio; PTT, partial thromboplastin time; VWF Ag, Von
Willebrand Factor antigen; %RCBA, percentage residual collagen binding activity;
%RCBAc, corrected percentage residual collagen binding activity post mixing with 1:1
pooled normal serum; VWFCP, Von Willebrand Factor Cleaving Protease activity, Inhibitor,
VWFCP inhibitor; ND, not done; SR, severely reduced.
CD4 Hb Platelets LDH INR PTT D-
Dimers
Creatinine VWF
Ag
%RCBA VWFCP %RCBA
c
Inhibitor
x106/l g/dl
x109/l U/l mg/l µmol/l %
1 242 4.6 14 15077 1.28 28.6 0.98 60 252 110.9 SR 72.7 yes
2 389 6.7 9 2335 1.2 37 4.98 136 179 98.8 SR 38.5 no
3 193 4.3 15 4772 1.45 30.9 1.22 65 263 92.8 SR 38.1 no
4 69 3.6 15 4962 1.08 27 0.9 68 114 34 Normal
5 283 6.3 12 4737 1.01 28.2 1.5 75 248 118.4 SR 24.3 no
6 ND 9.1 11 5085 1.03 27.6 1.38 97 265 109.9 SR 87.3 yes
7 144 5.4 36 6468 1.35 32.6 5.45 279 422 93.1 SR 41.6 no
8 87 4.2 5 3833 1.22 46.8 1.68 116 405 99.7 SR 23.5 no
9 138 4.1 17 1335 1.12 46.2 2.94 107 167 51.2 Borderline
10 17 5.9 22 1015 1.28 22.5 1.67 87 335 21.8 Normal
11 163 5.9 5 3166 1 29.7 4.14 95 181 113.3 SR 47.7 no
12 408 8.3 53 737 1.13 26.2 0.85 47 161 24.5 Normal
13 102 4.8 11 4052 1.27 32.6 4.93 1221 251 91.9 SR 44.8 no
14 89 5.2 12 2317 1.34 29.3 0.3 122 289 96.1 SR 71.2 yes
15 112 5.7 11 1948 1.22 26.5 ND 97 278 90.9 SR 75.3 yes
16 6 8.3 37 949 1.21 40 4.06 183 207 22.6 Normal
17 210 5.2 12 3400 1.14 39.2 3.27 78 294 103.3 SR 43.2 no
18 65 4.7 8 3086 1.1 25.5 2.02 81 202 40.1 Normal
19 818 4.9 10 4112 1.19 32.6 4.3 36 289 107.6 SR ND ND
20 ND 5.2 10 9750 0.84 22.8 0.6 90 279 100.5 SR 87.8 yes
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Table 9. Depiction of normal and reduced Von Willebrand Factor Cleaving Protease
(VWFCP) activity in 20 HIV positive patients with Thrombotic Thrombocytopenic Purpura.
Normal VWFCP activity
<50.5%RCBA
Reduced VWFCP activity
>50.5% RCBA
Patients 6 14
Inhibitors Not applicable 5
Figure 15 depicts that within the HIV positive group with TTP (Group 4) there is distinct
separation between a group with normal VWFCP activity (% RCBA less than 50.51%) and a
group with reduced VWFCP activity (% RCBA greater than 50.51%).
VWFCP activity of 20 HIV positive patients with
Thrombotic Thrombocytopenic Purpura
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Figure 15. Scatter plot of Von Willebrand Factor Cleaving Protease Activity (VWFCP) in 20
HIV positive patients with Thrombotic Thrombocytopenic Purpura (TTP). Normal VWFCP
activity is <50.5% RCBA) which is noted in 6 patients and Reduced VWFCP activity (>50.5%
RCBA) is noted in 14 patients.
As seen in Figure 16, within group 4, 13 patients showed reduced VWFCP activity (% RCBA
greater than 50.51%) and of these patients, in 5 patients there was no correction of % RCBA
to below the cut-off value upon mixing studies (indicating the presence of an inhibitor)
whereas in 8 patients there was correction of VWFCP activity (indicating the absence of an
inhibitor).
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Inhibitor assay of 13 HIV positive patients with
Thrombotic Thrombocytopenic Purpura and
reduced VWFCP activity
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Figure 16. Scatter plot of Inhibitor assay (50:50 mixing study of Residual Collagen Binding
Activity assay with normal pool sample) of 13 HIV positive patients with reduced Von
Willebrand Factor Cleaving Protease (VWFCP) activity. In 5 patients the % RCBA did not
correct to below 50.5% (inhibitor therefore present) and in 8 patients the % RCBA did correct
to below 50.5% (inhibitor therefore not present).
The data for Group 4 did not have a normal distribution (Shapiro-Wilk test) and could not be
normalised on log–transformation or square-root transformation. Non-parametric statistical
analysis was therefore applied to compare groups. Using the Wilcoxon rank-sum test, a
statistically significant difference was noted for the % RCBA between Group 4 (HIV positive
patients with TTP) and Group 1 (HIV negative controls), p<0.0001, between Group 4 and
Group 2 (HIV normal platelets) p=0.0001 and between Group 4 and Group 3 (HIV low
platelets) p=0.0003. Refer to Table 10 for a summary of this data.
Table 10: Summary of statistical analysis for Group 4 versus other Groups using the
Wilcoxon rank-sum test.
Pair Wilcoxon rank-sum Significance
Group 1 versus 4 p<0.0001 Different
Group 2 versus 4 p=0.0001 Different
Group 3 versus 4 p=0.0003 Different
%
RCBA
cut-off
50.51%
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Statistical analysis of the data for Group 4 (HIV positive patients with TTP) using the Kruskal-
Wallis test and Wilcoxon rank-sum test revealed significantly lower CD4 counts (p=0.0492)
and LDH levels (p=0.0168) and higher platelet counts (p=0.0282) at presentation in patients
with normal VWFCP activity. Reduced VWFCP activity in the absence of a detectable inhibitor
was associated with significantly higher D-Dimer levels (p=0.0108).
VWF antigen levels were high in all patients but those patients with severely reduced VWFCP
activity had significantly higher levels (p=0.0320) than patients with normal VWFCP activity.
No significant difference was found between patients with reduced VWFCP levels with and
without inhibitors (p=0.5582).
4.6 Graphical depiction of the summary of the four groups
Figure 17 depicts the four patient groups and highlight the similar distribution for groups 2 and
3 (HIV positive patients with both normal and low platelets) which is different from Group 1
(the HIV negative control group). The latter graph also highlights that Group 4 (HIV positive
patients with TTP) is distinctly different from the other groups.
Figure 17. Box and whisker plot comparing the % RCBA between the four different groups.
Group 1: HIV negative control patients;
Group 2: HIV positive patients with normal platelet counts;
Group 3: HIV positive patients with low platelet counts;
Group 4: HIV positive patients with TTP.
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4.7 Robustness of the assay
Various samples were re-run to assess the robustness of the assay.
When samples of 17 HIV positive patients with TTP were re-run, this showed results which
remained consistently below the defined % RCBA cut-off value for HIV positive patients
(50.51%).
Despite small differences in % RCBA in some cases, the results consistently fell below the
% RCBA cut-off value and thus clinical decisions would not be affected by these small
differences.
When samples of 20 HIV positive patients with TTP (from Group 4) were re-run, the % RCBA
remained consistently either above or below the % RCBA cut-off value in each patient.
Re-run of mixing studies in 5 HIV positive patients with TTP showed consistent results.
Of note is that undialysed and dialysed samples should be run on the ELISA plates
immediately, as freezing these samples and subsequently thawing and re-running at a later
point reveals significant discrepancies in % RCBA, such that the values for the same patient
in some cases are either below or above the designated % RCBA cut-off value. Thus freezing
and thawing of undialysed and dialysed samples affects analysis and is thus not
recommended as misclassification of the result (for example below the cut-off as opposed to
above the cut-off for % RCBA) would result in misdiagnosis.
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5. Discussion
5.1 TTP and VWFCP
Thrombotic Thrombocytopenic Purpura (TTP) is a disease characterized by microvascular
platelet aggregation and thrombus formation in selected tissue beds resulting in a pentad of:
thrombocytopenia, microangiopathic haemolytic anaemia, renal failure, neurological
symptoms and fever (Amorosi & Ultman, 1966; Cines, Konkle & Furlan, 2000; Moake, 2002;
Rock, et al., 2000). One cannot wait for the full pentad of symptoms of TTP to develop, as
early diagnosis full pentad and treatment are imperative for survival.
A possible key role for Von Willebrand Factor in the pathogenesis of TTP was first suggested
by Moake et al, in 1982 who postulated a deficiency of a VWFCP as the cause for the
presence of ULVWF multimers documented in the plasma of four patients with chronic
relapsing TTP (Moake, et al., 1982). In 2001, several groups identified ADAMTS13 (a
disintegrin-like and metalloprotease with thrombospondin type 1 motif 13) as the VWFCP
(Furlan, Robles & Lämmle, 1996; Tsai, et al., 1996) and deficiency of ADAMTS13 was
implicated in the pathogenesis of TTP (Furlan, et al., 1998).
The measurement of VWFCP activity in the setting of TTP as well as other pathological states
is a focus of much research (Levy, Motto & Ginsburg, 2005). One of the most common
haematological manifestations of HIV infection is thrombocytopenia which may be
multifactorial in nature. There is a broad differential diagnosis of thrombocytopenia, anaemia
and neurological dysfunction in patients with AIDS (Cines, Konkle & Furlan, 2000). It has long
been proposed that HIV infection predisposes to TTP and other TMA (Boccia, et al., 1984;
Jokela, Flynn & Henry, 1987). TTP may be the presenting clinical manifestation of HIV
infection, although the majority of cases occur in the context of AIDS (Hymes & Karpatkin,
1997).
Tamkus and colleagues, suggest consideration of TMA as an AIDS-defining illness so as to
facilitate the early recognition, effective treatment and improve survival of this life-threatening
but treatable condition (Tamkus, et al., 2006). The pathophysiology of TTP, specifically in the
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setting of HIV is not known and only limited data is available regarding VWFCP activity or the
presence of autoantibodies in these patients. Early diagnosis and treatment of TTP is
imperative for survival (Cines, Konkle & Furlan, 2000; Rock, et al., 2000; Levy, Motto &
Ginsburg, 2005) and assay of VWFCP levels can be useful in this regard. However, as the
therapy for TTP is very costly, improved diagnostic tools would be of value in confirming the
diagnosis of TTP.
5.2 The rapid collagen binding assay
There is currently no assay available in our laboratory setting for the measurement of
VWFCP. The semi-quantitative rapid collagen binding assay described by Rick and co-
workers, is an ELISA-based assay which relies on assessment of the residual collagen
binding activity (RCBA) of the patient’s own plasma-derived VWF.
Although this is only a semi-quantitative assay, it was chosen for use in our laboratory
because of its practical advantages in terms of cost-effectiveness (refer to Appendix A for a
breakdown of cost) and time effectiveness. It would therefore be suitable for routine use.
This assay is effective and reliable in the distinction between very low VWFCP activity and
normal or borderline VWFCP activity.
Samples can be stored frozen at -70 ºC and if required the samples can be batched, thereby
optimising resources. With the use of NUNC TM immunomodules, only the required number of
wells can be selected as opposed to using a full ELISA plate for a few patient samples,
thereby optimising cost.
With the use of very small concentrations of collagen (3μg/ml) batch/ lot variability is
eliminated as one purchase of Vitrogen TM Collagen (100mls) can be utilised for a very large
number of tests. A derivation of this assay is used to assess for the presence of an
associated inhibitor and is based on a mixing study. Inhibitor detection may have therapeutic
implications such as consideration of the benefit of associated steroid therapy (which may be
controversial in the setting of already immunocompromised individuals).
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In the multicentre study by Tripodi et al., comparing the results of measuring ADAMTS13 in
the same coded plasmas by 11 methods, the semi-quantitative collagen binding assay by
Rick et al., showed excellent reproducibility (average coefficient of variation of less than 10%),
relatively good linearity of expected versus observed results (r2 value 0.81) and intermediate
ability to discriminate between different VWFCP levels (Tripodi, et al., 2004).
This MMED study obtained an inter-assay coefficient of variation of 8.80% and an intra-assay
coefficient of variation of 4.83%.
The assay used was chosen for its practical advantages. Some limitations were identified. It is
a semi-quantitative assay based on residual VWF-collagen binding activity rather than direct
VWFCP measurements. This assay requires a 3 hour incubation period of plasma samples in
a denaturing environment (urea) in order to detect metalloprotease activity and may not
accurately reflect enzymatic activity under physiological flow conditions in vivo. The method
used for inhibitor analysis may not be sufficiently sensitive to detect weak inhibitors especially
as correction of RCBA back into the normal range for HIV positive patients (who have mildly
reduced protease levels compared to non HIV infected individuals) was taken as the defining
criteria to exclude an inhibitor. Moreover, non-neutralizing antibodies may be present which
accelerate ADAMTS13 clearance or inhibit binding (Scheiflinger, et al., 2003) but do not
interfere with its activity in vitro.
This assay tended to give disproportionately higher VWFCP measurements at the lowest
levels (Tripodi, et al., 2004) and other quantitative assays may have a more accurate
minimum detection limit. This may result in some false negative results, which may be
problematic and consideration of other laboratory and clinical correlation is imperative.
Tripodi and co-workers, do not report false positive results with the use of this assay, which
could result in patients with borderline clinical findings receiving inappropriate therapy. As a
semi-quantitative screening assay, this assay has advantages in terms of cost-effectiveness
and accommodation of many samples simultaneously.
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Initial studies by Studt and co-workers, revealed that the collagen binding assay appears to
be subject to disturbance and is delicate and some improvement in terms of accuracy is
required, although no systematic error was identified (Studt, et al., 2003). However, as per an
international collaborative study of eleven methods for ADAMTS13 by Tripodi and co-workers,
the best overall performance was noted for three methods: the ristocetin cofactor activity, the
collagen binding assay and the immunoblotting of degraded multimers of VWF substrate
(Tripodi, et al., 2004). Reproducibility studies demonstrated that the most precise methods
were the semi-quantitative collagen binding assay (as per Rick, et al., 2002) and the ristocetin
cofactor activity where the average coefficient of variation was less than 10% (Tripodi, et al.,
2004).
Tripodi and co-workers, conclude that a varied performance of the methods is noted and an
overall optimistic view of the reliability of currently available methods for ADAMTS13 detection
is supported (Tripodi, et al., 2004).The subsequent more recent assays for assessing
ADAMTS13 activity including the Enzyme-Linked Immunosorbent Assay using recombinant
VWF-A2 domain as a substrate used by Whitelock et al., and Zhou et al., and the FRETS-
VWF73 assay, used by Kokame et al., have not yet been compared in a multicentre trial
(Whitelock, et al., 2004; Zhou & Tsai, 2004; Kokame, et al., 2005). The latter two assays
appear to have practical advantages in terms of efficiency, although may not be as cost-
effective as the rapid collagen binding assay.
Currently there is no gold standard assay available in our laboratory setting for comparison.
Although other assays have subsequently become available since the commencement of this
MMED project, the rapid collagen binding assay remains a very cost-effective assay and is a
practical tool for screening VWFCP activity.
Freezing and thawing of undialysed and dialysed samples affected analysis in this study. Of
note, however is that as per Tsai & Lian, analysis of control plasma that was stored frozen for
at least 20 years did not have an adverse effect on VWFCP activity (Tsai & Lian, 1998).
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In the literature there are some references to the use of a serine protease inhibitor such as
Pefabloc SC TM, which is incubated with the plasma sample so as to prevent non-specific
proteolysis of VWF by other enzymes in plasma. Pefabloc SC TM (or other serine protease
inhibitors) serves to inhibit serine proteases in plasma samples (Shelat, Ai & Long Zheng,
2005; Furlan, et al., 1998; Furlan, et al., 1997; Zheng, et al., 2004). As per Rick and co-
workers, we did not use a serine protease inhibitor.
5.3 Findings in HIV positive patients
This MMED study established the optimal conditions for this assay in our laboratory and
ascertained the cut-off values for % RCBA (inversely proportional to VWFCP activity) in our
laboratory in the setting of HIV negative and HIV positive patients. VWFCP activity was also
measured in patients with HIV related thrombocytopenia (of any cause except TTP) in order
to assess whether this is the same as in HIV positive patients with normal platelet counts and
not markedly decreased which would preclude any diagnostic utility in HIV related TTP.
This study then compared VWFCP activity in HIV positive patients with low platelet counts
with HIV positive patients with normal platelet counts and HIV negative control patients.
The % RCBA for the HIV negative group (Group 1) was statistically significantly different from
the HIV positive group with normal platelets (Group 2), p=0.0001 and from the HIV positive
group with low platelets (Group 3), p=0.0006. However, the two HIV positive groups with
normal platelets (Group 2) and low platelets (Group 3) were not statistically significantly
different (p=0.7783).
The cut-off value of % RCBA for normal VWFCP activity in HIV positive patients was 50.51%,
as determined from the mean plus two standard deviations (as per Rick, et al., 2002) in 113
control patients with HIV infection but no TTP (Group 2 and Group 3 combined). This cut-off
value is higher than for HIV negative controls (37.12% determined from the mean plus two
standard deviations in Group 1) and this indicates mildly reduced enzyme activity in HIV
positive patients regardless of the platelet count. This concurs with the finding that VWF
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levels are increased in HIV positive patients (Aukrust, et al., 2000) and that there is a negative
association between VWF antigen levels and VWFCP activity (Mannucci, Capoferri &
Canciani, 2004).
Mildly decreased VWFCP activity has been described in numerous other disease states,
many of which may occur in association with HIV infection. Decreased VWFCP activity in
many of these pathological states, may also be on the basis of continued elevation of plasma
VWF due to chronic inflammation. However, additional factors such as proteolytic inactivation
of VWFCP by thrombin (Crawley, et al., 2005) in conditions which are associated with
coagulation activation (such as DIC), may contribute to down-regulation of VWFCP activity
and have relevance in the context of HIV infection.
Our finding of mildly reduced VWFCP activity in the setting of HIV infection (regardless of the
platelet count) does not preclude the diagnosis of TTP as only severely reduced VWFCP
activity is relevant. The mildly reduced VWFCP activity noted in HIV positive patients is
unlikely to affect the clinical utility in the diagnosis of TTP.
The specificity of low ADAMTS13 levels for the diagnosis of TTP has been debated in the
literature (Tsai 2003; Remuzzi, 2003). Severe deficiency of ADAMTS13 activity of less than
5% in a patient with clinical symptoms of an acute thrombocytopenia and evidence of a
microangiopathic haemolytic anaemia (in particular red cell fragments on peripheral smear)
appropriately defines the diagnosis of TTP. As severely deficient ADAMTS13 activity may not
always produce the clinical entity of TTP (Wyrick-Glatzel, 2004) the specificity of severely
reduced ADAMTS13 levels for TTP has been questioned. It is therefore essential to correlate
ADAMTS13 activity with other laboratory and clinical findings.
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5.4 Findings in HIV positive patients with TTP
Importantly, our study revealed that thrombocytopenia in the setting of HIV due to causes
other than TTP is not associated with severely reduced VWFCP levels thereby giving this
assay potential clinical utility in the diagnosis of HIV-related TTP. Therefore HIV positive
patients with TTP (Group 4) could be assessed as an additional component of this MMED
project
There was marked heterogeneity with respect to VWFCP activity and inhibitors in the setting
of TTP in HIV positive patients. Whilst the majority of such patients (70% in this study) have
severely reduced VWFCP activity (>90% RCBA), a significant minority (30% in this study) had
normal/borderline VWFCP activity (<50.5% RCBA). A statistically significant difference was
noted for the % RCBA between Group 4 (HIV positive patients with TTP) and Group 1 (HIV
negative controls), p<0.0001, between Group 4 and Group 2 (HIV normal platelets) p=0.0001
and between Group 4 and Group 3 (HIV low platelets) p=0.0003.
In acquired TTP such as that associated with HIV, it has been suggested that decreased
VWFCP activity is mediated by an inhibitor. In this study inhibitors were demonstrated in only
5 of 13 patients (~38%).
In a previous series of patients with HIV-related TTP, where VWFCP levels and autoantibody
levels were assessed, all 6 of the patients tested had reduced VWFCP levels, however none
had detectable inhibitors (Miller, et al., 2005). The absence of inhibitors in a subset of our
patients concurs with the findings of Miller and co-workers.
A case report by Sahud and co-workers, describes an IgG inhibitor associated with complete
absence of VWFCP activity in the plasma of one patient with HIV-related TTP (Sahud, et al.,
2002). An additional two patients with HIV-related TTP with complete deficiency of VWFCP
and a strong inhibitor to VWFCP were apparently later identified by the same group (Sahud,
et al., 2002).
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Although the rapid collagen binding assay has some limitations, in view of the apparent
heterogeneity of HIV-related TTP, it seems probable that factors other than immune inhibition
of VWFCP activity may result in the development of TTP, at least in some HIV positive
patients. One consideration is that there is endothelial cell injury due to either direct infection
by the HIV virus (Del Arco, et al., 1993; Miller, et al., 2005) or mediated by inflammatory
cytokines (Lafrenie, et al., 1996) which may result in release of large quantities of stored
VWF. This overwhelms VWFCP capacity and a ‘consumptive deficiency’ of the enzyme
ensues. A more focal or milder process may result in a relative VWFCP deficiency which is
restricted to the milieu of the affected tissue bed, despite overall normal circulating levels of
VWFCP.
A more diffuse or more severe process may result in absolute VWFCP deficiency thereby
resulting in significantly reduced measured VWFCP activity in the absence of an inhibitor.
In either scenario, high molecular weight VWF multimers would accumulate with activation of
platelets in affected tissue beds. In addition, endothelial cell damage with associated loss of
the inherent endothelial thromboresistant properties would enhance the deposition of platelet
rich thrombi which result in the development of thrombotic microangiopathy. There is
supporting evidence of this idea. Markedly elevated VWF plasma levels have been
documented in HIV-infected patients (Aukrust, et al., 2000).
Reiter and co-workers, demonstrate transient appearance of ULVWF multimers and loss of
VWFCP activity following the infusion of DDAVP which stimulates the release of stored VWF
from endothelial cells (Reiter, et al., 2003). The ability of overwhelming VWF release to
exhaust VWFCP activity is supported by the latter study by Reiter and co-workers.
In this MMED study, increased VWF antigen levels were documented in all patients and as
would be predicted, patients with severely reduced VWFCP activity had significantly higher
VWF antigen levels than patients with normal/borderline VWFCP activity (p=0.0320).
In the absence of any other coagulation parameter abnormalities, elevated D-Dimer levels is
reported in HIV-related TTP (Gunther & Dhlamini, 2007). This may reflect localized
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coagulation activation secondary to endothelial injury with resultant overwhelming VWF
release and loss of endothelial thromboresistance. This finding would therefore support the
above considered mechanism.
Notably in this MMED study, D-Dimer levels were significantly higher in patients with reduced
VWFCP activity without inhibitors (p=0.0108). In the latter patients, VWF release may
constitute the primary pathogenic event. In contrast, in patients with inhibitors, the release of
VWF may only provide the necessary ‘second hit’ precipitating an acute episode of TTP.
Crawley and co-workers, described the down-regulation of VWFCP activity by thrombin and
plasmin (Crawley, et al., 2005). Thrombin and Plasmin (generated during coagulation
activation) may assist in explaining the association between raised D-Dimer levels and
reduced VWFCP activity in the absence of inhibitors and may also contribute to thrombotic
microangiopathy development in these patients.
In this MMED study, normal VWFCP activity was significantly associated with lower CD4
counts (p=0.0492), higher platelet counts (p=0.0282), lower LDH levels (p=0.0168).
In TTP patients with normal VWFCP levels, an alternative possibility is that mechanisms
unrelated to VWF cleavage may be responsible for the formation of platelet thrombi.
The degree of endothelial injury may be great enough to eliminate the normal endothelial
thromboprotective anticoagulant properties and induce platelet adhesion, aggregation and
thrombus formation in very severely affected patients. Therefore, even in the absence of
accumulation of ULVWF multimers, this could give rise to the clinical features of TTP.
In this MMED study, this is supported by the significant correlation of normal VWFCP levels
with lower CD4 counts and more advanced retroviral disease and the pathogenesis of TTP in
these patients may be related to significant endothelial damage.
The existence of alternate pathogenic mechanisms for TTP, have also been suggested
outside of HIV-related TTP. In approximately 40% of patients with acquired idiopathic TTP,
VWFCP deficiency may not be the cause of microvascular platelet thrombi (Lian, 2005). The
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formation of microvascular platelet thrombi in patients with acquired TTP without VWFCP
deficiency may be caused by endothelial injury and/or platelet aggregation triggered by
various stimuli that may be related to inflammation, infectious agents, immune response or
chemicals (Lian, 2005). Some triggering agents may cause vascular injury/platelet
aggregation and result in TTP without VWFCP autoantibody formation (Lian, 2005).
A larger sample size of TTP patients would have been of value and further studies of TTP
both in the setting of HIV positive and negative individuals is required.
This MMED study demonstrates a fairly limited number of patients with inhibitors to VWFCP
in the setting of HIV and TTP. This may explain the clinical observation that TTP in patients
with HIV is highly responsive to simple plasma infusion therapy and may not require plasma
exchange (Novitsky, et al., 2005). However, further studies would be necessary to attempt to
correlate VWFCP activity and inhibitors (possibly using assays that directly measure VWFCP)
with specific clinical data and clinical response in HIV-related TTP. This may be of value in
further elucidating and confirming the pathogenesis of HIV-related TTP and in establishing the
utility of such investigations as a routine tool to guide and monitor response to therapy.
Lämmle and co-workers, suggest that due to problems with static protease activity assays,
not all patients diagnosed with idiopathic TTP may have severe VWFCP deficiency (Lämmle,
Kremer Hovinga & Alberio, 2005). In contrast however, Lian, suggests that as not all patients
diagnosed with idiopathic TTP have severe VWFCP deficiency, there may be other different
aetiological causes for idiopathic TTP aside from severe VWFCP deficiency (Lian, 2005).
Although standardisation of VWFCP assays is required with the establishment of a universal
cut-off value for the diagnosis of TTP, data from this MMED study supports the heterogeneity
of the pathogenesis of TTP. This assay has potential as a routine tool to guide therapy,
monitor response to therapy and assess prognostic significance of both HIV positive and HIV
negative TTP patients.
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6. Conclusion
The rapid collagen binding assay is a practical cost-effective assay for the assessment of
VWFCP activity which could be instituted as a routine laboratory assay to enhance diagnostic,
therapeutic follow-up and research aspects pertaining to TTP. A derivation of this assay
based on mixing studies for the assessment of VWFCP inhibitors, may have therapeutic
implications such as consideration of concomitant steroid therapy as well as provide further
information regarding the pathogenesis of TTP.
This study demonstrates that although semi-quantitative, the rapid collagen binding assay
described by Rick and co-workers is practical and effective in the distinction between very low
VWFCP activity and normal/borderline VWFCP activity, for which various explanations have
been proposed. We established that in the setting of HIV, regardless of the platelet count,
there is a baseline reduction in VWFCP activity. This study established our own cut-off values
for VWFCP activity in the setting of HIV negative (% RCBA > 37.12%) and HIV positive
patients (% RCBA > 50.51%) and showed that there is no difference in VWFCP levels in HIV
positive patients with low platelet counts versus normal platelet counts.
This study showed that thrombocytopenia in the setting of HIV due to causes other than TTP
is associated with only mildly reduced VWFCP levels and it is not associated with severely
reduced VWFCP levels. The baseline mild deficiency of VWFCP in the setting of HIV would
not impair the use of this assay for the diagnosis of TTP, as it is severe deficiency of VWFCP
(associated with microangiopathic haemolytic anaemia, thrombocytopenia and appropriate
clinical findings) that is associated with TTP. Thus this assay has potential clinical utility in the
diagnosis of HIV-related TTP.
However, use of this assay in the setting of HIV-related TTP demonstrates clear
heterogeneity with regard to VWFCP activity and inhibitors in the context of HIV positive
patients with TTP, suggesting that other factors are likely to interact in the setting of HIV
infection to produce the same clinical end-point.
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Thus VWFCP levels cannot be used in isolation to exclude a diagnosis of TTP in HIV. Despite
the heterogeneity of the pathogenesis of TTP in the setting of HIV, assessment of VWFCP
activity is still relevant to the diagnosis of TTP, especially to assess for severely reduced
VWFCP activity. Moreover, determining VWFCP activity and inhibitors with this assay is of
relevance in elucidating the pathogenesis of TTP in HIV, which appears to be a
heterogeneous disease.
Further studies are needed to confirm this as the number of HIV positive TTP samples
obtained were small and it would be useful to run similar studies using alternate assays to
verify these findings. No specific assay is as yet accepted in the literature as a gold standard
and ongoing research with standardisation of VWFCP assays is required in order to attempt
to establish a universal cut-off value for VWFCP activity for the diagnosis of TTP.
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7. Appendices
Appendix A: Estimated Cost per VWFCP test excluding labour
Table 11: Estimated cost per VWFCP test excluding labour: January 2006-01-22
Slide-A-Lyser TM per plate (20 patients & 1 control=21) R357-00
Superblock TM per plate R93-00
Vitrogen TM Collagen per plate R0-28
NUNC TM ELISA per plate R11-00
NUNC TM Sealing tape per plate(R2.15x4=R8.60) R8.60
Rb a Hu Von Willebrand Factor /HRP per plate R18-98
ABTS TM tablets per plate R18-65
ABTS TM buffer per plate R10-28
Estimated cost of Urea, Barium Chloride, NaCl, Tris, PBS tablets per plate R5-00
Estimated Cost of Consumables per plate (pipette tips, gloves) R5-00
Total R527.79
20 tests per plate therefore:
Estimated cost per VWFCP test excluding labour R26.38
Appendix B: Summary of statistical analysis for Group 4
Table 12: Depiction of summary of statistical analysis of significant correlations for Group 4.
The Kruskal-Wallis test and Wilcoxon rank-sum test were used.
Number Mean score p-value
Variable: CD4 count
Reduced VWFCP 12 11.25
Normal VWFCP 6 6 p=0.0492
Variable: Platelet count
Reduced VWFCP 14 8.607143
Normal VWFCP 6 14.916667 p=0.0282
Variable: LDH level
Reduced VWFCP 14 12.571429
Normal VWFCP 6 5.666667 p=0.0168
Variable: D-Dimer level
Inhibitor present 4 2.75
No inhibitor 8 8.375 p=0.0108
Variable: PTT
Inhibitor present 5 3.4
No inhibitor 8 9.25 p=0.0083
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Table 13: Depiction of summary of statistical analysis of correlations of Von Willebrand Factor
antigen levels for Group 4. This was assessed in HIV positive patients with Thrombotic
Thrombocytopenic Purpura (TTP), in the setting of reduced versus normal Von Willebrand
Factor Protease activity and then with and without an inhibitor. Analysis performed using the
Wilcoxon rank-sum test.
Number Rank Sum p-value
Variable: VWF antigen
Reduced VWFCP 14 173 p=0.0320
Normal / Borderline
VWFCP 6 37
Variable: VWF antigen
Inhibitor present 5 39 p=0.5582
No inhibitor 8 52
Appendix C: Summary of data of % RCBA for Group 1, Group 2 and Group 3
Table 14: Summary for average, median, standard deviation and cut-off values of % RCBA
for Group 1, Group 2 and Group 3.
Group 1 Group 2 Group 3
average 27.06% 33.02% 32.41%
n 70 55 58
median 26.97% 30.45% 30.55%
stdev 0.050308 0.085894 0.092216
cut-off 37.12% 50.18% 50.85%
average cut-off group 2 & 3 50.51%
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Appendix D: Data of 4 ELISA plates blocked with Superblock TM versus Casein.
Table 15: Comparison of data from 4 ELISA plates blocked with Superblock TM versus
Casein.
Superblock™ Dry Blend
(Samples 1-38)
Casein (0.5g)
(Samples 1-38)
Average % RCBA 33.12% 43.9%
Minimum % RCBA 19.4% 30.8%
Maximum % RCBA 53.3% 67.9%
Average Undialysed
Absorbance
0.59 0.32
Average Dialysed
Absorbance
0.19 0.14
Antibody + Substrate 0.12 0.11
Substrate 0.07 0.08
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